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Abstract 
Bioproduction of therapeutic proteins such as monoclonal antibodies (mAb) continues to 
be a fast growing sector of advanced manufacturing. An ever increasing repertoire of 
therapeutic proteins coupled with the emergence of biosimilars has led to increasing global 
demand for higher yielding, faster, and more cost-effective manufacturing process. Central 
to any good production platform is the capacity of the production cell line. A suitable 
production cell line exhibits physiological traits such as high specific productivity (qp), short 
doubling time, high peak cell density and efficient metabolism. The emergence of a 
suitable production cell line with all the aforementioned traits is an extremely rare event, as 
it requires that all facets of cellular transcription, translation, secretion and metabolic 
efficiency are both individually optimized and collectively synchronized into a system 
capable of high level protein expression.  
 
Cellular translation and secretion capacity is thought to be one of the major cellular 
bottlenecks limiting protein production in mammalian cells. The over-expression of 
complex recombinant proteins such as mAbs driven by strong viral promoters exerts 
considerable burden on the Endoplasmic Reticulum (ER) and Golgi apparatus. Increased 
ER stress triggers the Unfolded Protein Response (UPR), which may lead to cell apoptosis 
and thus elimination of cells with high expression of the Gene of Interest (GOI). In this 
thesis, we adopted a host cell engineering approach to expand cellular translation and 
secretion capacity prior to expressing the GOI, in order to increase the probability of 
isolating high producers. Through screening of a panel of mAb producing clonal cell lines 
using qPCR, the XBP1 mRNA splice ratio was identified as a suitable target to augment 
host cell translation and secretion machinery. A high ratio of spliced over unspliced XBP1 
mRNA is required to overcome the negative regulatory effect of unspliced XBP1 protein. 
Spliced XBP1 mRNA translates into a potent transcription factor that up-regulates a wide 
range of folding, secretory and quality control proteins, which forms the cytoprotective 
branch of the UPR.  
 
A stable CHO host cell line engineered with a high splice ratio of XBP1 mRNA exhibited 
increased expression of various chaperone and secretary vesicle proteins without 
increasing UPR associated apoptotic markers. This engineered host cell line was 
compared against the parental cell line in transient mAb production studies. The XBP1 cell 
line displayed a 7.5 fold increase in qp over the control cell line and more than 4 fold 
increase in final volumetric productivity. Moreover, a 3-fold increase in the percentage of 
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high producers was observed in the cell distributions post-transfection when using the 
XBP1 host cell line. mAb producing cells derived from the XBP1 host cell line also 
demonstrated competency in conventional stirred-tank bioreactors, showing promise of a 
commercially viable production platform.  
 
In conclusion, XBP1 mRNA splice ratio engineered host cells have expanded translation 
and secretion capacity to alleviate the ER stress experienced from mAb production. The 
augmented capacity enabled multi-fold improvements in qp and volumetric productivity 
and increased the frequency of high producers in the transformed pool. The engineered 
host cell line showed great promise to become a commercially viable production platform 
cell line to significantly reduce the time and resources associated with cell line 
development.  
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3C12   In house IgG4 monoclonal antibody 
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ADCC   Antibody-dependent cell-mediated cytotoxicity 
APC   Allophycocyanin 
bZIP   Basic Leucine Zipper 
CHO   Chinese Hamster Ovary 
DHFR   Dihydrofolate reductase 
dO2   Dissolved oxygen 
eIF2α   Eukaryotic translation initiation factor 2A 
ELISA   Enzyme-Linked Immunosorbent Assay 
ER   Endoplasmic Reticulum 
ERAD   Endoplasmic-reticulum-associated protein degradation 
FACS   Fluorescent Activated Cell Sorting 
GFP/eGFP  Green Fluorescent Protein/Enhanced Green Fluorescent Protein 
GOI   Gene of Interest 
GS   Glutamine synthetase 
IgG   Immunoglobulin G 
IRE1   Inositol-requiring enzyme-1 
IRES (aIRES) Internal ribosome entry site/attenuated Internal ribosome entry site 
mAb   monoclonal antibody 
NaHCO3  Sodium bicarbonate 
ORF   Open Reading Frame 
PEI   Polyethylenimine 
PERK   PRKR-like endoplasmic reticulum kinase 
qp   Cell specific productivity 
qPCR   Quantitative Polymerase Chain Reaction 
RFU   Relative Fluorescent Unit 
STR   Stirred Tank Reactor 
UPR   Unfolded Protein Response 
XBP1-S  X-box binding protein 1- Spliced 
XBP1-US  X-box binding protein 1-Unspliced 
1. Introduction 
1.1 The Unfolded Protein Response 
The Unfolded Protein Response (UPR) is a critical cellular response of Endoplasmic 
Reticulum (ER) stress triggered by the accumulation of unfolded or mis-folded proteins 
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within the ER [1-4]. UPR is conserved across eukaryote cells with varying degrees of 
complexity [5-7]. Mammalian UPR is an extensively studied cellular response as it is 
believed to play a critical role in a variety of human disease conditions such as diabetes, 
cancer, neurodegenerative disorder and inflammation (reviewed in [8]). Mammalian UPR 
consists of three principal pathways governed by their respective trans-ER-membrane 
proteins: PERK, IRE1 and ATF6 pathways [1, 2, 9-12] (Figure 1). The three pathways 
respond in parallel but also with significant cross-talk to alleviate ER stress through the 
following responses: translation attenuation, ER assisted degradation (ERAD) of mis-folded 
proteins, expansion of ER and Golgi capacity, and – finally – an apoptotic response if ER 
stress cannot be mitigated [5, 12-18]. The interplay between the three pathways culminates 
into a dichotomy of cytoprotective and apoptotic responses of the UPR [19]. 
 
Figure 1. Overview of mammalian UPR depicting the three pathways [19]. 
 
1.1.1 PERK pathway 
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of the three 
principal pathways of the UPR. The PERK pathway responds to ER stress initially through 
translation attenuation to lessen the protein synthesis demand in ER; however, if ER stress 
persists, PERK promotes the activation of apoptotic signaling. PERK pathways begin at the 
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detection of unfolded protein through the dissociation of PERK bound BiP – a representative 
molecular chaperone involved in protein folding. This dissociation is followed by 
oligomerization of PERK for its activation [20, 21]. Activated PERK alleviates the translation 
load through phosphorylation of serine 51 of the alpha subunit of eukaryotic initiation factor 
(eIF2α), which inhibits its ability to recruit Met-tRNA in the formation of the translation 
initiation complex [22]. While phosphorylation of eIF2α attenuates general translation, it 
favors translation of Activating Transcription Factor 4 (ATF4). Translational regulation of 
ATF4 depends on its 2 upstream open reading frames (uORF) [23]. In unstressed cells, 
ribosomal scanning reach uORF2 and initiate translation, which inhibits translation of ATF4. 
However, during ER stress phosphorylation of eIF2 will reduce availability of the eIF2-GTP 
translation initiation complex, causing the ribosome to scan through the inhibitory uORF2 
and initiae translation the ATF4 start codon [23]. This mechanism enables ATF4 translation 
to counter the general translation suppression caused by eIF2α phosphorylation. ATF4 
belongs to a large group of basic leucine zipper (bZIP) transcription factors that recognize 
cAMP response elements (CRE) in the promoter regions of numerous genes [24]. Some of 
the genes regulated by ATF4 are involved in amino-acid metabolism, redox chemistry and 
mitochondrial functions [25]. Furthermore, ATF4 can form homodimer and heterodimers with 
other binding partners to regulate an even broader range of gene targets [24]. Within the 
context of UPR, the most crucial binding partners of ATF4 are members of the C/EBP protein 
family, specifically C/EBP homologous protein (CHOP) [26] also known as GADD153. 
CHOP is a 29kDa transcription factor consisting of a N-terminal trans-activator domain and 
a C-terminal bZIP domain that includes a dimerization motif [27]. The induction of CHOP 
during UPR is thought to promote cell arrest and apoptotic signaling pathways through its 
interaction with anti- and pro- apoptotic Bcl-2 family proteins [28-31]. There are no known 
CHOP binding sites in the Bcl-2 promoter region, but McCullough et al. reported that ectopic 
over-expression of CHOP represses the expression of Bcl-2 proper and the authors 
speculated indirect repression of Bcl-2 through alternate binding partners of CHOP. The 
authors also observed perturbation in the cellular redox state and an increase of Reactive 
Oxygen Species (ROS) resulting in increased sensitivity to oxidative injuries [29]. 
Puthalakath et al. demonstrated that transcriptional regulation of CHOP increased 
expression of pro-apoptotic BH3 domain only Bcl-2 family protein, Bim. The authors 
observed the concurrent increase in expression of CHOP and Bim mRNA in ER stress 
induced mice thymocytes, but no increase in Bim mRNA in CHOP-/- mice thymocytes. They 
have also identified possible binding sites for CHOP heterodimer in the Bim promoter region 
[31].  
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1.1.2 ATF6 pathway 
ATF6 is a constitutively expressed 90kDa trans-ER-membrane protein capable of sensing 
ER stress. It is activated through proteolysis to release its transcription factor domain [11, 
32]. In mammalian cells ATF6 exists in two closely related forms, ATF6α and ATF6β, 
however only ATF6α displays transcriptional activities [33, 34]. Similar to PERK, ATF6 
detects unfolded protein in the ER lumen through dissociation of ATF6 bound BiP. Unlike 
PERK, which requires oligomerization for activation, ATF6 is translocated to the Golgi 
apparatus for proteolysis to release its active domain [35]. In unstressed state, BiP is bound 
to the ATF6 ER luminal tail, which encodes for Golgi localization signal [36]. The dissociation 
of BiP due to preferential binding to unfolded proteins [37] exposes the Golgi localization 
signal resulting in translocation to the Golgi apparatus ,where its cytosolic portion is cleaved 
by site-1 (S1P) and site-2 (S2P) protease [38]. The liberated cytosolic ATF6 is a 50kDa 
soluble bZIP transcription factor that localizes to the nucleus [11]. Once translocated to the 
nucleus, ATF6 dimerize with another transcription factor, Nuclear Factor-Y (NF-Y), to 
recognize a unique 19 nucleotide sequence (CCAAT-N9-CCACG) [32, 39, 40]. This 
sequence, known as the ER stress response element (ERSE), is commonly found in the 
promoter regions of mammalian UPR target proteins.  
 
ATF6 regulates a distinct set of UPR targets to PERK-ATF4 targets. Using a microarray in 
conjunction with inducible ATF6 over-expression, Okada and colleagues identified a subset 
of UPR targets that is induced specifically by ATF6 and not PERK [41]. The authors reported 
that ATF6 regulates mostly molecular chaperones and folding enzymes, whereas PERK-
ATF4 regulates genes involved in amino acid biosynthesis and metabolism. Both ATF6 and 
PERK pathways showed synergetic up-regulation of CHOP. Adachi et al. further expanded 
the microarray study to include genome-wide search of ATF6 targets and revealed its 
involvement in protein quality control through regulation of ERAD proteins [42].  
1.1.3 IRE1 pathway 
IRE1 or Inositol Requiring Enzyme 1 encoded by the human ERN1 gene is central to the 
most evolutionarily conserved UPR pathway [43], and the IRE1 pathway is the only UPR 
pathway in single cell eukaryotes such as Saccharomyces cerevisiae [19]. In mammalian 
cells there are two homologs of IRE1; IRE1α is ubiquitously expressed in all tissues while 
IRE1β is only expressed in gastrointestinal epithelium [44]. IRE1 is a trans-ER-membrane 
Serine/Threonine protein kinase, which upon the detection of unfolded proteins in the ER 
lumen activates and performs splicing on its mRNA target [15, 45, 46].  
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IRE1 can be divided into three domains: the luminal domain for sensing ER stress, the 
transmembrane domain and the cytosolic domain, which features kinase and ribonuclease 
activities [47]. The luminal domain is responsible for detecting unfolded proteins within the 
ER lumen, however the exact mechanism of ER stress detection is still debated. The 
disagreement is centered on whether BiP dissociation, unfolded protein binding to IRE1 or 
both is critical for activation [20, 45, 47-52]. The mechanism of activation involves IRE1 auto-
phosphorylation, which promotes IRE1 self-association to oligomerize and form a high-order 
structure [45]. The oligomerization event allows the RNase region of IRE1 cytosolic domain 
to form the active substrate binding pocket [45, 47]. Mutation studies performed on IRE1 
oligomerization sites revealed that failure to the form the high-order clusters inhibits the 
splicing of its substrate [53, 54]. In yeast cells, IRE1 mediates the splicing of HAC1 mRNA, 
which is then ligated by tRNA ligase Rlg1p to yield a functional HAC1 transcription activator 
that up-regulates ER specific chaperone and folding proteins [55]. In mammalian cells and 
other metazoan, HAC1 is replaced with XBP1 mRNA [15] which also up-regulates 
cytoprotective and pro-survival genes. The role of XBP1 in mammalian cells will be 
elaborated in later section.  
 
Apart from activation of XBP1, IRE1 can also trigger apoptosis during prolonged ER stress. 
Currently there are two observed IRE1-mediated apoptotic events: the c-JUN NH2-terminal 
kinase (JNK) and Regulated IRE1-Dependent Decay (RIDD) pathways. JNK belongs to the 
Mitogen-activated protein kinase (MAPK) superfamily, which can be activated through 
numerous cellular stress cues such as UV radiation, heat shock or inflammatory cytokines 
[56]. Activated JNK phosphorylates c-Jun, which dimerize with c-Fos to form the AP-1 
transcription factor that plays critical role in regulating cellular functions including apoptosis 
[56]. IRE1-mediated JNK activation is thought to be triggered through oligomerization of 
TRAF2 adaptor protein thus initiating signaling cascade similar to that of the Tumor Necrosis 
Factor (TNF) receptor signaling [57]. TRAF2 protein was observed to interact with the C-
terminal cytosolic portion of IRE1 through two-hybrid and co-precipitation methods [58]. At 
the onset of ER stress and subsequent IRE1 oligomerization event, the high-order assembly 
of IRE1 also promoted the oligomerization of cytosolic bound TRAF2 protein, which is 
necessary for the downstream activation of JNK pathway [58]. The other IRE1 mediated 
apoptotic event is the RIDD pathway triggered by the enduring phosphorylation and 
oligomerization of IRE1 if ER stress is not abated. The chronic oligomerization of IRE1 brings 
about the degradation of ER-localized mRNA in addition to normal XBP1splicing activity [59-
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61]. This inhibition of ER and secretory protein synthesis may amplify pro-apoptotic UPR, 
which drives the cell to terminal apoptosis. Recent research discovered regulated IRE1-
dependent decay (RIDD), where IRE1 can regulate cellular functions through splicing of 
non-coding RNA and other micro-RNAs [62, 63].   
1.1.3.1 XBP1 
The primary target of IRE1 is the splicing of HAC1/XBP1 mRNA to yield an active 
transcription factor to instigate adaptive UPR and cell survival response [15, 18, 64, 65]. The 
active XBP1 protein will hence forth be referred to as XBP1-S, spliced variant as opposed 
to XBP1-US, unspliced variant. XBP1 mRNA is constitutively expressed at low level in 
mammalian cells [15], and unlike conventional mRNA splicing, XBP1 splicing was observed 
to occur in the cytoplasm instead of the nucleus [66]. The mammalian equivalent of yeast 
ligase Rlg1p responsible for the ligation of HAC1/XBP1 mRNA has not been identified nor 
cloned, but it is believed to exist in the cytoplasm rather than nucleus [66]. The splice site in 
mammalian XBP1 mRNA forms two stem loop structures and IRE1 excise 26 nucleotides, 
which causes a frameshift in the mRNA transcript resulting in a new Open Reading Frame 
(ORF) [15]. The two XBP1 protein isoforms share identical N-terminus, but due to the 
frameshift change, the original Stop codon is displaced to the end of mRNA (Figure 2). As 
a result they have contrasting C-terminus and size; XBP1-US is predicted to be 
approximately 29kDa, while XBP1-S is larger at 40kDa and contains a potent transcription 
activator in its C-terminus. Following IRE1 mediated splicing, XBP1-S protein is translocated 
to the nucleus for the up-regulation of its target genes [67].  
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Figure 2. XBP1 splicing event summarized. 
 
The XBP1 N-terminus, shared between both isoforms contains a DNA binding bZIP domain 
which recognizes cis-acting elements in the promoter region of UPR target genes. Similar 
to activated ATF6, XBP1 is capable of binding to ERSE found in the promoter region of ER 
resident chaperones [68], but it is also capable of binding to the mammalian Unfolded 
Protein Response Element (UPRE) found in the promoter region of a particular subsets of 
UPR genes [69] such as those involved in the ER Associated Degradation (ERAD) [69]. 
ERAD is a critical component of UPR, which systemically remove unfolded proteins with 
exposed hydrophobic patches or immature glycans [70]. In addition to ERSE and UPRE, 
there have been reports of XBP1 binding to other cis-acting elements such as ERSE-II [71] 
and ACGT core [72]. However, the role of these response elements and their exact 
involvement in UPR are difficult to describe fully due to the significant overlaps in the three 
UPR pathways especially between XBP1 and ATF6 pathways. The interactions of ATF6 and 
IRE1-XBP1 on UPR are critical in the time-dependent mitigation of ER stress. Activation of 
ATF6 is a rapid response activated through cleavage of a pre-existing ER membrane bound 
precursor, which is then translocated to the nucleus to perform gene regulation, whereas 
XBP1 requires activation/oligomerization of IRE1 for splicing followed by translation of 
XBP1-S protein, which would delay the effects of XBP1. The targets of XBP1 are seen as a 
more sustained response as opposed to the rapid on/rapid off response of ATF6, a view 
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supported by the fact that by proteins responsible for transportation and secretion such as 
SEC23, SRP54, SSR3 and SPCS3 are targets of XBP1 and not ATF6 [42]. 
 
In addition to its involvement in the mitigation of ER stress during UPR, XBP1 also has 
crucial involvement in the proper development of highly secretory cells [73-77]. XBP1-/- 
mouse fetuses demonstrated embryonic lethality caused by liver apoptosis [73]. Lee and 
colleagues developed an in vivo method where XBP1-/- mouse fetuses obtained ectopic 
expression of XBP1 in the liver driven by liver-specific promoter sequence, however the 
mouse fetuses died shortly after birth due to hypoglycemia resulting from severe impairment 
in the production of pancreatic digestive enzymes [75]. Furthermore, exocrine gland cells 
such as saliva gland acinar cells also demonstrate severe impairment in ER formation and 
ER chaperone proteins expression. Another essential role of XBP1 is in the differentiation 
of antibody producing plasma cells from mature B-lymphocytes [74]. During the humoral 
immune response, naïve B lymphocyte are activated by antigens to be transformed into 
mature B cells which are ready to receive cytokines such as Interleukin 4 to further 
differentiate into antibody secreting plasma cells [78]. Plasma cells are characterized by 
their capability to secrete a large amount of antibodies [79, 80] and XBP1-S has been 
identified as a necessary and defining factor in plasma cell differentiation [18, 74, 81, 82]. 
During plasma cell differentiation, the cell size dramatically increase, followed by 
corresponding increase in ER size and up-regulation of proteins associated with the ER and 
secretory machinery [18, 82]. In B cells derived from XBP1 deficient mice, ectopic 
expression of XBP1 is essential to induce the phenotypic changes that characterize plasma 
cells (increased cell size, expanded ER/Golgi and increased protein synthesis) [18]. Further, 
microarray analysis revealed that XBP1 targeted genes were involved in every step of the 
secretory pathway. Similarly, in an in vitro model of mouse plasma cell differentiation, XBP1 
is critical for the formation of proper ER structures and XBP1 deficient plasma cells are 
functionally defective in the secretion of IgG [83]. Interestingly, despite the critical 
involvement of XBP1 in plasma cell differentiation, conventional UPR activation is not 
observed during differentiation. While IRE1 splicing is critical in the induction of plasma cell 
differentiation, the PERK and ATF6 pathways are not activated [84-86]. Moreover, the 
induction of XBP1 precedes onset of antibody mRNA and protein synthesis [82, 87]. Taken 
together, this suggests that XBP1 induction and functions can be decoupled from ER stress 
stimulated UPR (Figure 3 [88]). 
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Figure 3. Annotated downstream targets of mammalian XBP1-S transcription factor [88]. 
1.2 Biopharmaceuticals 
Biopharmaceuticals or Biologics describes a class of therapeutic products that is extracted 
or manufactured from biological sources. Examples of biopharmaceuticals include vaccines, 
stem cell products, gene therapy and recombinant therapeutic proteins. In 2013, global sales 
for biopharmaceuticals reached USD$140 billion, with the top 10 selling products achieving 
combined global sales of USD$70 billion [89]. Biopharmaceuticals exhibit much larger 
compound size and more complexity in their structure compared to conventional chemically 
synthesized drug compounds. Other significant differences between the two classes of 
therapeutics are summarized in Table 1. Biopharmaceuticals are often produced as 
replacement therapy for insufficient or flawed native proteins such as insulin, human growth 
hormones, erythropoietin and monoclonal antibodies (mAbs). Among the different classes 
of biopharmaceuticals, monoclonal antibodies (mAbs) represents the largest product class 
by revenue, with a combined value of USD$63 billion [89]. Due to its importance and 
potential future growth outlook, this thesis will focus on the bioproduction of mAbs.  
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Property Small Molecules Therapeutic Proteins 
MW Low molecular weight (<1000 Da) High molecular weight (>> 1000 Da) 
Preparation Chemical synthesis Biologically produced, can be engineered 
Physicochemical 
properties Mostly well defined 
Complex—tertiary structure—undergo 
post transcriptional modifications, e.g. 
glycosylation 
Route of 
administration Oral administration usually possible Usually administered parenterally 
  Rapidly enter systemic circulation through blood capillaries 
Reach circulation primarily via 
parenteral route: iv, direct; or sc via 
lymphatic system 
Distribution To any combination of organs/tissues/cells 
Usually limited to plasma and/or 
extracellular fluids 
Metabolism 
Metabolized typically by liver and gut 
CYPs into nonactive and active 
metabolites 
Catabolism by proteolytic degradation 
to peptides and amino acids 
Serum half-life Short serum half-lives Relatively long serum half-lives 
Typical dosing 
regimen Suitable for QD or BID dosing Dosing usually far less frequent 
Toxicity Can produce specific toxicity due to parent or metabolites (often “off target”) 
Mostly receptor mediated toxicity, 
including both super pharmacodynamic 
responses and biological toxicity (often 
“exaggerated pharmacology”) 
Species 
reactivity 
Generally active in multiple animal 
species Relevant and irrelevant animals models 
Antigenicity & 
hypersensitivity 
Nonantigenic, but can show 
unpredictable hypersensitivity 
Potential for antigenicity (with MW > 10 
kDa) 
Clearance 
mechanisms 
Small molecules and therapeutic proteins do not share clearance mechanisms—
noncompeting, parallel 
Drug–drug 
interactions 
Pharmacokinetic interactions due to 
competing clearance mechanisms 
Less common, less well-defined - Decreasing clearance if there is enzyme inhibition 
- Increasing clearance if there is 
enzyme induction 
Pharmacology Tends to mimic or interrupt ligand interaction with its receptor or enzyme 
May interact with receptor but the 
biologic may be the ligand (hormone 
replacement therapy) or bind to the 
ligand, it may be a soluble receptor 
(decoy therapy) or may be an enzyme 
Table 1. Comparison of Properties of Small-Molecule Drugs and Biomolecular Drugs [90]. 
 
Monoclonal antibodies are large proteins of approximately 150kDa comprising four subunits, 
two identical pairs of heavy and light chains. The subunits are held together by varying 
numbers of disulfide bonds to give the antibody its distinctive Y shape structure. The 
antibody can be divided into two regions: the antigen-binding region Fab (Fragment, antigen-
binding) which encompass the two arms of Y structure, and the region which constitutes the 
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trunk of the Y structure, the Fc region (Fragment, crystallizable). Fab, as the name implies, 
is responsible for antigen recognition and binding, and each antibody recognizes a specific 
antigen structure [91]. The Fc region is critical to elicit antibody effector function upon binding 
to an antigen. These effector functions includes blocking of bound receptors, cell lysis 
through complement dependant cytotoxicity (CDC), recruitment of effector cells through 
antibody dependant cellular toxicity (ADCC) and triggering of phagocytosis of pathogens.  
 
The complexities of large therapeutic proteins such as mAbs mean that they can only 
perform their functions if they retain the correct structural conformation. Moreover, variations 
in their post-translational modifications can significantly alter their pharmacodynamic and 
pharmacokinetic properties [92, 93]. Due to their large size and complexity, it is not feasible 
to manufacture biopharmaceuticals via traditional chemical synthesis; this is especially the 
case for therapeutic proteins like mAbs [94]. Therefore, biopharmaceuticals are 
manufactured in biological systems with the most popular and widely adopted being 
bacterial, yeast and mammalian cells [95]. In recent years, alternate production platforms 
are being investigated such as in whole plants [96], moss (P.patens) [96] and transgenic 
animals [97], but they are still in technological infancy and are unlikely to gain regulatory 
approval in the near future. Among all available production platforms, Chinese Hamster 
Ovary (CHO) cells is the workhorse cell line of choice in today’s biopharmaceutical 
manufacturing [89, 94].  
 
Since its original isolation and immortalization close to 60 years ago [98], CHO cells have 
been extensively used as a model system for the study of mammalian molecular genetics. 
Their robustness and ease of growth even in partially defined culture medium combined with 
the ease of identifying phenotypical mutants derived from genetic perturbations made CHO 
cells suitable as a model system. Early genetic studies on dihydrofolate reductase (DHFR) 
created a CHO cell line with knock-out of one DHFR allele and a mutation in the second 
DHFR allele [99]. This DHFR deficient CHO cell line known as CHO-DXB11 cannot grow in 
the absence of thymidine and hypoxanthine, and this growth restriction had a profound 
impact on the future adoption of CHO cells as production hosts. The metabolic deficiency of 
CHO-DXB11 can be repaired through transfection with plasmid DNA encoding a functional 
DHFR gene, which forms the basis for transformant selection when used in conjunction with 
the transfection of a Gene of Interest (GOI) [100]. The selection method paved the way for 
the manufacture of large, complex proteins in mammalian cells, with the first approved 
biopharmaceutical manufactured in CHO cells being recombinant tissue plasminogen 
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activator (tPA). Since the approval of tPA, CHO cells have become standard in the 
production of biopharmaceuticals due numerous attributes. Firstly, they are robust cells 
capable of adapting to various cultivation conditions with the most significant being their 
ability to grow in suspension culture in chemically defined medium, which is a pre-requisite 
with today’s manufacturing practices. Secondly, CHO cells can perform human-like post-
translational modifications which can increase proteins bioactivity while reducing 
immunogenicity [101]. Thirdly, there are well established gene amplification methods to 
rapidly increase the product yield in CHO cells, such as the aforementioned DHFR system 
and the Glutamine Synthetase (GS) system which will both be discussed in greater details 
later. Finally, the continued propagation of CHO cells as the production platform also 
resulted in cumulative research and understanding of its biology and this is favored by the 
regulatory authorities.  
1.2.1 Biopharmaceutical Manufacturing 
The production cost of biopharmaceuticals is significantly higher than traditional chemical 
synthesis. This is compounded by the high dosage requirement for antibody treatment 
resulting in considerable burden for the patients and the healthcare system; antibody 
treatments costs around USD$35,000 per patient per year [102] and upward of 
USD$400,000 per year for treatment of rare conditions [103]. In order to meet the market 
demand for therapeutic proteins like mAbs, current industrial production facilities can house 
a total site capacity as high as 200,000L and capital investment in excess of USD$600 
million. The manufacturing Cost of Goods (COG) also incurs significant costs for antibody 
production, with manufacturing COG reported to represent 20% to 25% of the sales revenue 
[102]. The manufacturing COG is strongly influenced by the production titer. One techno-
economic model showed that a 10-fold increase in production titer from 0.5g/L to 5g/L 
decreases COG by 85% from $124/g to $16/g [104]. High costs drives innovation in the 
biologics processes and the development of more efficient and predictable host cell lines is 
a central requirement. Due to its prevalence and significance in the biopharmaceutical 
industry, extensive research has been conducted to understand CHO cells in the context of 
a production platform. Perhaps the most significant research topic is on methods to increase 
productivity in CHO cells. Overall product titer coalesces to the combination of two 
parameters: integral of viable cells and the cell specific productivity (qp). In modern 
recombinant protein production, the GOI is often driven by strong viral promoters such as 
the human cytomegalovirus (CMV)[105] or Simian virus 40 (SV40) promoters [106]. These 
viral promoters ensures that the GOI is abundantly transcribed, however GOI mRNA copy 
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number does not necessary equate to final product formation [107-109]. The increased 
translation and secretion demand from the increase in GOI mRNA leads to accumulation of 
mis-folded and aggregated product in the host cell [108, 109] and it is generally accepted 
that the rate-limiting step in mammalian bioproduction lies in the translation and secretion 
machinery [107, 110, 111].  
1.2.2 Host Cell Engineering 
It is highly desirable to engineer improved host cell lines as a platform for bioproduction, as 
it may increase the product titer, product quality, reduce cell line development time, and 
remove unwanted traits from the production host. The availability of a good cell platform is 
critical as it allows the user to consistently generate considerable material in shorter time 
frame. The potential to produce substantial high quality products can save considerable time 
and resources during cell line development while the familiarities with cell behavior can fast-
track the bioprocess optimization. As product titer is the function of the cell specific 
productivity (qp) and the integral of viable cells (IVC), the myriad of approaches to enhance 
the production host has focused on two broad areas; improving cell growth and survivability 
or increasing productivity and quality. Figure 4 outlines the conventional Cell Line 
Development process and the impact of rationale host cell engineering of the translation and 
secretion machinery.  
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Figure 4. Summary of Cell Line Development Process. 
 
Cell growth and survivability can be improved through the modifications of the apoptotic 
pathway. A popular approach to engineer apoptotic resistant cell line is targeting the Bcl-2 
family proteins and various targets within the caspase induced apoptotic pathway [112-116]. 
Over-expression of anti-apoptotic proteins; Bcl-2 and Bclx(L) in CHO cells has been 
demonstrated to increase cell survivability in the presence of common bioprocess induced 
stress such as ammonia accumulation and nutrient deprivation [117]. The anti-apoptotic cell 
engineering has also been combined with other host cell engineering strategies in synergy. 
Jeon et al. applied a combinatorial engineering approach to create host CHO cell line over-
expressing Bcl-2 while simultaneously down-regulating lactate dehydrogenase A (LDH-A) 
with siRNA to counter the inhibitory effect of lactate build-up during mid-to-late stage 
culturing to support high viable cell density and culture longevity [118]. Other metabolic 
manipulations have also been employed to improve the cellular efficiency leading to 
increased biomass. A popular approach is the substitution of glucose with galactose or 
fructose to limit lactate production rate, as the cellular affinity for fructose/galactose uptake 
26 
 
is much lower than glucose [119]. This method to limit lactate production was adapted into 
host cell engineering, Wlaschin et al. introduced fructose transporter encoded by GLUT5 
gene into CHO cells and cultured in high fructose medium and found that one of the clones 
demonstrated lowered lactate production and a 3-fold increase in cell density [120]. Another 
cell engineering approach to limit lactate production targeted the down-regulation of LDH in 
the conversion of pyruvate to lactate using siRNA and have achieved success in terms of 
increased product titer [121, 122].  
 
The cell specific productivity or qp can have a significant impact on process efficiency as 
improvement on product to biomass ratio can reduce downstream burden. The separation 
of biomass from product can be challenging in high biomass processes such as perfusion, 
where the culture can be extremely viscous due to the accumulation of biomass. The highly 
viscous culture not only limits harvest strategies but also increases the likelihood of filter fail. 
Therefore, numerous efforts are focused on improving qp which, besides the increase in 
product titer, may also allow more flexibility in downstream processes. As previously 
mentioned, the translation and secretion machinery has often been alluded as the rate-
limiting step in product formation. Molecular chaperones and ER resident folding proteins 
are popular targets for over-expression to improve qp, Table 2 outlines the strategies of 
translation and secretion enhancement and their effect on the productivity. Due to its 
significant involvement in protein translocation and folding, BiP is one of the first ER proteins 
to over-express in host cell enhancement for bioproduction. However, it was found that the 
over-expression of BiP in antibody secretion cells did not enhance the productivity [123]. 
Another popular target for improving protein synthesis is Protein disulfide isomerase (PDI) 
which facilitates the formation of disulfide bonds to hold the protein in its correct structure or 
to hold multimeric proteins such as antibodies. There was mixed success with the over-
expression of PDI family proteins to improve bioproduction [123-126]. Borth et al. reported 
37% increase in cell specific secretion rate in mAb expression CHO cells transfected with 
PDI. However, other investigators such as Davis et al. reported that over-expression of PDI 
did not improve the productivity in cells expressing di-sulfide bond rich interleukin [124]. 
Moreover, a more recent study investigating the effect of PDI over-expression in 
bioproduction employed industrially relevant CHO cells grown in chemically defined medium 
also found no improvements from PDI [126]. The authors concluded from their flux analysis 
that due to the complexity of protein synthesis and folding, and the involvement of multiple 
folding proteins/chaperones the up-regulation of PDI alone does not have sufficient impact 
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on final productivity. Therefore, some researchers started to focus their efforts on 
transcription factors which are responsible for the regulation of multiple genes.  
Target Product Result Reference Year 
SNARE   positive Peng 2011 
PDI mAb positive Borth 2005 
PDI Fc fusion protein negative Davis 2000 
PDI interleukin no effect Davis 2000 
PDI thrombopoietin no effect Mohan 2007 
PDI antibody some effect Mohan 2007 
BiP and PDI mAb negative Borth 2005 
BiP mAb negative Borth 2005 
ERp57 (PDI) thrombopoietin positive Hwang 2003 
Calnexin and calreticulin thrombopoietin positive Chung 2004 
Various secretion targets mAb positive Peng 2009 
XBP1 SEAP positive Tigges 2006 
XBP1 mAb positive Gulis 2014 
XBP1 tPA negative Rahimpour 2013 
XBP1, ERO1 mAb positive* Cain 2013 
XBP1 EPO some effect Ku 2010 
Table 2. Summary table of translation and secretion related cell engineering approaches. 
 
Perhaps the most well-known target for translation and secretion engineering is XBP1-S. 
The first published work on the over-expression of XBP1-S to achieve improved 
bioproduction was by Tigges et al. [127]. In their work, they’ve demonstrated significant 
improvement in the transient expression of secreted reporter proteins through XBP1-S co-
transfection. Their work concurred with prior understanding that only XBP1-S will have 
positive impact on bioproduction compared with ectopic expression of XBP1-US. Their 
stable XBP1-S cell line also exhibited enlarged ER and Golgi along with increased 
expression of ER chaperone protein Erdj4. Ku et al. reported that they observed no 
productivity improvements in the over expression of XBP1-S in IgG and interferon γ 
producing cells [128]. However, they did observe an increase in productivity in transient co-
transfection of XBP1-S and Erythropoietin (EPO). Taken together, the authors concluded 
that ectopic expression of XBP1-S for improved bioproduction is only beneficial in cell lines 
expressing secretory stress. In their subsequent work [79], they’ve further showed that 
transient EPO production correlated with the amount of XBP1-S mRNA. Moreover, in stable 
EPO expressing CHO cells the authors observed a drop in EPO expression upon siRNA 
knock-down of XBP1-S. However, in line with their previous attempts, the authors did not 
observe any correlations between XBP1-S expression level and IgG product titer. There are 
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also several studies where the authors observed no improvement in the over-expression of 
XBP1-S on bioproduction, this is especially the case for larger more complicated proteins 
such as mAb (150kDa) or human Factor VIII (>200kDa) [129-131]. The expression of large 
and complicated proteins such as mAbs may place significantly more demand on cellular 
translation and secretion capacity. Thus, this may explain the limited improvement in product 
yield when concerned with mAbs. Further, these studies adopted similar strategies to 
express XBP1-S in recombinant protein producing cells. There are also studies where 
improvement was observed through a combinatory approach of over-expression of XBP1-S 
along with other cell engineering targets such as folding proteins ERO-1 [132] or apoptosis 
inhibitor XIAP (x-linked inhibitor of apoptosis) [133]. Overall, the literature results in XBP1-S 
based cell engineering for improved bioproduction is inconsistent and has a mixed success 
rate. Granted, therapeutic protein bioproduction is a complicated process with variables from 
the transcription of GOI all the way to the secretion of final product. Compounding the 
problem is that productivity is often protein and/or cell line dependent. 
 
1.3 Project Aims 
This project aims to create a platform cell line with enhanced translation and secretion 
capability through host cell engineering. We will perform a comparative study on mAb 
producing clonal CHO cell lines with focus on examining the difference in their translation 
and secretion machinery. In particular, we will be examining the role of XBP1 as it will be 
our prime target for cell engineering. XBP1 is a global transcription factor and plays the 
dominant role in the cytoprotective response during the Unfolded Protein Response. Its 
positive effects on translation and secretion capacity have been well documented and we 
believe that its effect will be tremendously valuable to bioproduction. Due to the mixed 
success reported in the literature on improving productivity with XBP1, we will take more 
innovative approach to cell engineering. 
 
We will seek to further understand several key translation/secretion related gene targets on 
productivity. These targets include folding proteins, ER quality control proteins, secretion 
related proteins and both XBP1 splice variants. We will then select several mAb producing 
CHO clonal cell lines with a range of productivity levels and examine the correlation between 
our gene targets and productivity. It is imperative that clonal cell lines are selected for the 
comparative study to reduce variability associated with stable pools. The comparative study 
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should provide us with more insight on how to modify the translation and secretion 
machinery.  
 
Our approach will focus on host cell engineering because we believe that translation and 
secretion engineering is only beneficial prior to the introduction of the GOI. As the literatures 
have shown, there were no improvements in the over-expression of XBP1-S in producing 
cell lines. We believe that this is due to an unintended selection process post-transfection 
which has often been overlooked. When the cells are transfected with the vector containing 
viral promoter to drive the GOI, it immediately incurs significant burden on 
translation/secretion, thus triggering UPR. The cells which have survived the initial 
transfection are the ones which have either sufficient translation/secretion capacity to cope 
with the increase demand or they have been poorly transfected and have low copies of the 
GOI. This also leaves an unfortunate scenario where effectively transfected cells were 
consigned to apoptosis as they do not possess sufficient downstream machinery to match 
the demand. Therefore, by preconditioning the cell through enhanced translation and 
secretion machinery, we believe this will increase the probability to retain the effectively 
transfected cells and increase the overall quality of the resistant pool. More-over, such cell 
lines will also benefit in transient bioproduction due to the same challenge of sudden 
increase in ER burden. We will also adopt engineered resistant pool as our host cell platform 
as opposed to an engineered clonal cell line. The rationale is to retain genetic diversity within 
the host cell line so it can be adapted to produce various recombinant proteins. Different 
recombinant proteins may elicit diverse responses to the host cell and impact on the 
productivity. Therefore, it is important to retain diversity in the host cell line to accommodate 
for the variety of recombinant proteins and have the opportunity to select the most suitable 
production clone. Our approach is focused on raising the baseline output of our host cell 
while retaining its population diversity.   
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2. Materials and Methods 
2.1 General Cell Culture Techniques 
All cell lines used in this thesis were derivatives of CHO-XL99, which itself is a suspension 
and serum-free adapted CHO-K1 (ATCC CCL-61) cell line. All cell lines are cultured in 
humidified 5% CO2 incubators with shaking at 130rpm 2.5cm shaking radius. The cell lines 
are passaged on a 2, 2, 3 days passaging schedule to ensure cultures are always in mid-
log growth phase. Cell density and viability are determined using trypan blue exclusion on 
Cedex HiRes Automated Cell Counter (Roche, Basel, Switzerland). Cells are passaged by 
seeding the inocula to a final cell density of 0.3 x 106 cells mL-1 in fresh pre-warmed medium 
to make up a final volume of 20mL in a 125mL vented cap shaker flask (Cat#: 431143, 
Corning Inc, New York, USA).  
 
2.2 Generation of mAb producing clones 
The mAb producing clones were isolated by the National Biologics facility using 
electroporation followed by clonal isolation with ClonePix FL system. 1x107 CHO-XL99 cells 
cultured in CD-CHO (Cat#: 10743-029, Life Technologies, Carlsbad, USA) growing in mid-
log phase were pelleted by centrifugation at 233g for 10 min and supernatant removed by 
gentle pipetting. The cell pellet was resuspended in 600µL of fresh CHO-SFMII medium 
(Cat#: 12052-098, Life Technologies) and aliquot into 0.4cm electroporation cuvette (Cat#: 
165-2088, Bio-Rad, Hercules, USA) with 20µg of plasmid DNA added. The plasmid DNA for 
3C12 contains 3C12 Heavy and Light chain driven by human CMV promoter with GS and 
Puromycin selection agent. The cuvette was then placed on the Bio-Rad Gene Pulser 
Xcell™ and electroporated with a single pulse of square wave at 250V for 30 milli-seconds. 
Following electroporation, the cells were pipetted into 10mL of recovery medium of 50% CD-
CHO/50% CHO-SFMII supplemented with 8mM of glutamine and 0.5g L-1 of recombinant 
human albumin (Cat#: A6608, Sigma-Aldrich, St Louis, USA) in a T-75cm2 flask (Cat#: 
430641, Corning Inc). The culture was then placed to recover in 37oC humidified incubator 
with 5% CO2 for pH control for 48 hrs. Following recovery, the culture was then split into two 
methods for clonal isolation; direct plating onto ClonePix FL and generation of stable pool.  
 
Direct plating onto ClonePix FL for clonal isolation.  
80,000 cells mL-1 of the electroporated culture following recovery were added to 10mL of 
room temperature CloneMedia-CHO-G (Cat#: K8730, Molecular Devices, Sunnyvale, USA) 
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in a 50mL tube supplemented with 50mM MSX, 10µg mL-1 Puromycin, 100U mL-1 
CloneDetect-FITC (Cat#: K8205, Molecular Devices) and 0.5g L-1 recombinant human 
albumin. The cells and semi-solid medium were mixed by gentle swirling in the 50mL tube 
before gentle pouring onto 1 well Petriwell plate (Cat#: W1005 Molecular Devices). The 
poured plate was then placed into humidified incubator for 2 weeks undisturbed. Following 
2 weeks of incubation, the plate was then placed onto ClonePix FL automated colony picker. 
Individual colonies were picked and deposited into 96 well plates for expansion with 200µL 
of CD-CHO medium supplemented with 50mM MSX, 10µg mL-1 Puromycin and 0.5g L-1 
recombinant human albumin. Once the clones reached confluency in 96-well plate, they are 
up-scaled into 12-well non tissue culture treated plate with the same medium and 
commenced shaking before eventually growing in 125mL vented cap shaker flasks (Cat#: 
431143, Corning Inc.).  
 
Construction of Stable pool followed by clonal isolation with ClonePix FL 
Following the 48hrs recovery of electroporated CHO-XL99, the culture was inoculated into 
125mL vented cap shaker flask at 1x106 cells mL-1 with CD-CHO supplemented with 50mM 
MSX and 10µg mL-1 Puromycin. The selection continued for 2 weeks with routine passages 
to maintain cell density at 1x106 cells mL-1. Following 2 weeks of the selection process the 
stable pool was then seeded into 10mL of CloneMedia-CHO-G supplemented with 50mM 
MSX, 10µg mL-1 Puromycin, 100U mL-1 CloneDetect-FITC at 1000 cells mL-1. Following 
mixing by gentle swirling, the cell/medium mix was poured onto 1 well Petriwell plate and 
incubated in humidified incubator for 2 weeks undisturbed. The ensuing clonal isolation and 
expansion using ClonePix FL system was identical as previously described.  
 
2.3 Sandwich ELISA 
Enzyme-link Immunosorbent Assay (ELISA) was performed with; primary antibody - goat α 
human IgG Fc specific antibody (Cat#: 109005098, Jackson Immunoresearch) and 
secondary antibody – sheep α human kappa chain specific antibody conjugated to 
peroxidase (Cat#: AP015, Binding Site, Birmingham, UK). Nunc MaxiSorp® flat-bottom 96 
well plate (Cat#: 439454, Termo Fisher Scientific) was coated with 100µL of primary 
antibody diluted 1:1000 in PBS and incubated at room temperature for 1 hr. The plate was 
then washed 3 times in 180µL of PBS with 0.1%(v/v) Tween-20. Following the wash, the 
ELISA plate is incubated in blocking buffer of PBS-T with 0.5%(w/v) skim milk powder for 1hr 
at room temperature. After incubation in blocking buffer, the plate is washed 3 times with 
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PBS-T. The standard use for ELISA is purified 3C12 with concentration determined using 
HPLC. Samples and Standards were diluted with blocking buffer before loading 100µL into 
each well and incubated for 1hr. Following incubation, the plate was washed 3 times with 
PBS-T and 100µL of secondary antibody diluted 1:8000 in blocking buffer was then added 
and allowed to incubate for 30min. The plate was wash 3 times in PBS-T followed by the 
addition of 100µL of TMB substrate (Cat#: T0440-1L, Sigma-Aldrich). The reaction was 
stopped after 10min with the addition of 100µL of 2N H2SO4 and the absorbance at 450nm 
was collected on SpectraMax M5 (Molecular Devices). A standard curve was constructed 
and the slope and y-intercept of the linear regression was used to calculate the concentration 
of unknown samples.  
 
2.4 Calculation of Cell Specific Productivity (qp) 
The Cell specific productivity (qp) was calculated from the estimated Integral of Viable Cells 
(IVC) with the following formulae; 
Accumulated IVC for each day (IVCi) is first calculated using the below formula. 
 
Where (Xv) is viable cell density in 106 cells mL-1 and (t) is time in days. 
The cell specific productivity for each day (qpi) can then be derived. 
 
Finally, the overall qp for the production is the averaged qpi over the production period. 
 
Only qpi where the cells are viable are taken into the calculations. Once the culture enters 
death phase, the time point is no longer considered for qp calculations. 
 
2.5 Cell surface staining of secreting IgG 
2×106 cells growing in mid-log phase or cells from 48 hrs post-transfection were collected 
by centrifugation at 233g for 10min. The cells were washed twice with PBS by repeated 
centrifugation and resuspension. Staining solution was prepared by 1:100 dilution of 
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polyclonal APC conjugated goat α human IgG Fc specific antibody (Cat#: 109135098, 
Jackson Immunoresearch, West Grove, USA) in Hanks Balanced Salt Solution (Cat#: 
14025092, Life Technologies). 200µL of staining solution was then added to the cells and 
incubate in the dark for 30min at room temperature. Following staining, the cells was again 
washed twice in PBS and subjected to flow cytometry analysis. 
 
2.6 Flow cytometry analysis 
BD FACS Aria IIIu (BD Biosciences, San Jose, USA) equipped with 488nm and 633nm 
lasers were used to excite GFP and APC respectively. Fluorescent emission was collected 
through 502nm long pass filter followed by a 530/30 band pass filter for GFP signal and 
695/40BP filter for APC signal. Forward vs. Side Scatter signals were used to gate for viable 
cells followed by doublet discrimination using signal Height vs. Width.  
 
2.7 RNA Extraction, cDNA synthesis and Quantitative Real-time PCR (qPCR) 
using Viia 7 
Sample collections for qPCR were collected either 48hrs after cell passage or 48hrs post-
transfection. 5x106 cells were harvested by centrifuging at 4000g for 10min, and 
supernatants discarded. The cell pellet was resuspended in 500µL of RNAlater RNA 
Stabilization Reagent (Cat#: 76104, Qiagen, Venlo, Netherlands) and stored in -20oC until 
required. Total RNA was purified using Qiagen RNeasy Mini Kit (Cat#: 74104, Qiagen) 
according to manufacturer’s recommendations. The cells were homogenized by passing the 
cell sample through a 20G needle 5-6 times. On-column DNase I digestion was performed 
by incubating the RNA bound spin-filter with 100U of DNase I (Cat#: 18068015, Life 
Technologies) at room temperature for 15min. Following the elution of total RNA with ddH2O, 
the total RNA concentration was determined using Nanodrop 2000 (Thermo Fisher Scientific, 
Waltham, USA). The quality of total RNA was also assessed using 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, USA) to ensure RNA Integrity Number or >9.  
 
Total RNA was converted to cDNA using SuperScript III First-Strand Synthesis System 
(Cat#: 18080051, Life Technologies). The conversion was performed according to the 
manufacturer’s recommendations. For each reaction 4µg of total RNA were used and Oligo 
dT primers were used to convert only the mRNA. The reaction was performed at 50oC for 
50min. RNase H was added to remove the template RNA. The cDNA mix was then dilute 
1:10 in DNase/RNase free water prior to use.  
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The qPCR was performed on ABI ViiA7 instrument (Life Technologies) in opaque 384-well 
plate format. The 10µL total reaction mix includes; SYBR® Select Master Mix (Life 
Technologies), 2µL of diluted cDNA template, 200nM final concentration of both forward and 
reverse primer (descriptions of the primers used for qPCR are listed in Table 2). The qPCR 
conditions are as follow; 1 cycle of 95oC hold for 10min, 40 cycles of 95oC 15sec denaturing 
and 60 oC 1min 1-step annealing and extension and finally the construction of melt curve at 
0.05 oC per sec. The consistency of melt curve was used as quality control of the reaction. 
The reference genes for normalization are c.griseus GAPDH and Mgat1. 
 
2.8 Cloning of XBP1 reporter construct 
The XBP1 reporter construct used a modified sequence from CHO XBP1 Unspliced 
sequence (NCBI Reference Sequence NM_001244047.1). The Stop codon was replaced 
with the sequence ACGGATCC which include BamHI restriction enzyme site (Full sequence 
constructed by GeneArt can be found in Appendix A1). The modified sequence was 
synthesized from GeneArt® Gene Synthesis service (Life Technologies). The modified 
sequence was digested using HindIII and BamHI along with in-house mammalian 
expression GFP vector. The GFP expression vector is driven by human CMV promoter with 
multiple cloning sites located on the N-terminus of GFP sequence. After restriction enzyme 
digest, the fragments are separated using 1% agarose gel electrophoresis. The target 
fragments is cut out and gel extracted using QIAquick Gel Extraction Kit (Cat#: 28740, 
Qiagen), subsequently, both vector and gene cDNA are ligated with Rapid DNA Ligation Kit 
(Cat#: 11635379001, Roche).  
 
2.9 Generation of Stable resistant cell lines 
Stable cell lines (resistant pools) were generated from Lipofectamine 2000 (Cat#: 11668019, 
Life Technologies) mediated transfection followed by selection for 3 weeks in selection 
medium. Cells growing in mid-log growth phase are centrifuged at 233g for 10min and the 
supernatants removed. The cell pellet is then resuspended in 8mL CHO-SFMII medium 
(Cat#: 12052098, Life Technologies) to final concentration of 1.2x106 cells mL-1 in a 125mL 
vented cap shaker flask. 15µg of plasmid DNA and 37.5µL of Lipofectamine 2000 were 
separately diluted into 1mL of OptiPro SFM medium (Cat#: 12309019, Life Technologies) 
and allowed to incubated at room temperature for 5min. After incubation, the Lipofectamine-
OptiPro mix is added to the plasmid DNA in OptiPro and mixed gently by pipetting, the 
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complex formation is left undisturbed at room temperature for 25min. Following complex 
formation, it is then added to the cell culture and returned to the humidified incubator. 4-6hrs 
post-transfection 10mL of pre-warmed CHO-SFMII is added to the transfected culture and 
returned to humidified incubator. 48hrs post-transfection, the culture was centrifuged at 233g 
for 10min and the supernatants removed. The transfected cells are then resuspended in 
fresh selection medium to final cell concentration of 1x106 cells mL-1. The selection medium 
is culture medium supplemented with 400µg mL-1 final concentration of G418 (Cat#: 
10131027, Life Technologies) or 50mM MSX along with 10µg mL-1 Puromycin depending 
on the resistant gene on the plasmid DNA. After the addition of selection agent, the culture 
is passaged every few days to maintain the cell density at approximately 1x106 cells mL-1. 
Following 3 weeks of growth in selection medium, the resulting cell line is now considered 
the stable pool (resistant pool).  
 
2.10 Cloning of bicistronic XBP1-S IRES GFP construct 
Chinese Hamster (c. griseus) XBP1-spliced variant cDNA was obtained from cell samples 
of CHO-XL99 treated with 1µM of thapsigargin (Cat#: T9033, Sigma-Aldrich) for 24hrs. Total 
RNA extraction and cDNA synthesis were as previously describe in Section 6.7. The primers 
used to clone out CHO XBP1-S are; 
Forward primer 5’ GCTAGCGCCGCCACCATGGTGGTGGTGGCAG 3’  
Reverse primer 5’ AAGCTT TTAGACACTAATTAGCTGGGGAAA 3’.  
The forward primer included a NheI restriction enzyme cut site followed by Kozak 
mammalian translation initiation sequence, while the reverse primer included HindIII site. 
The PCR was performed with Platinum® PCR SuperMix High Fidelity (Cat#: 12532016, Life 
Technologies) with the following conditions; 30 cycles, 30 sec denaturation at 94oC, 30 sec 
annealing at 58oC, 1 min 30 sec extension at 68oC. The PCR product is then separated with 
1% agarose gel electrophoresis and the band of interest excised and gel extracted using 
QIAquick kit. CHO XBP1-S fragment is then sub-cloned to TOPO® TA Cloning kit (Cat#: 
450641, Life Technologies) to allow for restriction enzyme digestion with NheI and HindIII 
along with the in-house mammalian expression vector. The mammalian expression vector 
driven by human CMV promoter contains Glutamine Synthase (GS) and Puromycin 
resistance genes as selection markers, in addition the vector also contains a multiple cloning 
site upstream of Internal Ribosome Entry Site. Full vector map can be found in Appendix A2. 
Once CHO XBP1-S is cloned into the in-house expression vector, it will henceforth be 
referred to as pNBF-XBP1S. pNBF-XBP1S is then sent for sequencing at the Australian 
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Genome Research Facility Ltd. (Brisbane, Australia) and compared to the available CHO 
XBP1-S sequence (NM_001244049.1) from NCBI. There were two mutations on the XBP1-
S cDNA sequence obtained from CHO-XL99 (Appendix A3.1), but resulted in only one 
amino-acid change in the translated protein sequence, a S7A mutation (Appendix A3.2). 
Large quantities of pNBF-XBP1S plasmid DNA was obtained using PureLink® HiPure 
Plasmid Filter Maxiprep Kit (Cat#: K210017, Life Technologies).   
 
2.11 Fluorescent Activated Cell Sorting of high XBP1 splice ratio population 
For the generation of High XBP1 mRNA splice ratio cell line, we employed FACS to isolate 
the high XBP1-S populations. The plasmid DNA incorporated an IRES-GFP element for the 
quantification of amount of XBP1-S expression. The IRES-GFP allows the XBP1-S and GFP 
to be present on the same mRNA by translated separately, therefore giving a more accurate 
indication of XBP1-S expression level. FACS was performed on BD FACS Aria IIIu with 
previously mentioned setup. Stable pool of XBP1-S-IRES-GFP are prepared for cell sorting, 
the sample is concentrated into 1x107 cells mL-1 by centrifugation and resuspension. Cells 
in the top 10% of high GFP intensity were sorted using electric field deflection plates into 6 
well tissue culture treated plates with 3mL of recovery medium. The recovering medium for 
sorting is DMEM-F12 (Cat#: 11320033, Life Technologies) supplemented with 20% Fetal 
Bovine Serum and Penicillin/Streptomycin. 150,000 cells are deposited into each well. The 
cells are allowed to recover for 1 week in static culture in humidified incubator. After one 
week of static culturing, sorted cells are detached using TriPLETM Select (Cat#: 12563029, 
Life Technologies) and re-inoculate into shaker flask with original suspension culture 
medium. The enriched population is henceforth referred to as XBP1 cell line. 
 
2.12 PEI mediated transient transfection 
Transient bioproduction is performed with Polyethylenimine (PEI) mediated transfection, PEI 
used in all transient transfections was linear PEI Max (Cat#: 24765-2, Polysciences Inc, 
Warrington, USA) dissolved in ddH2O. Cells growing in mid-log growth phase are centrifuged 
at 233g for 10min and the supernatants removed. The cell pellet is then resuspended into 
8mL culture medium to final concentration between 1.2 to 3.6 x106 cells mL-1 in a 125mL 
vented cap shaker flask. 20 to 60µg of plasmid DNA and 1µg to 4µL DNA to PEI ratio were 
separately diluted into 1mL of OptiPro SFM medium and allowed to incubate at room 
temperature for 5min. After incubation, the PEI-OptiPro mix is added to the plasmid DNA in 
OptiPro and mixed gently by pipetting, the complex formation is left undisturbed at room 
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temperature for 15min. Following complex formation, it is then added to the cell culture and 
returned to the humidified incubator. 4-6hrs post-transfection 10mL of pre-warmed culture 
medium were then added to the transfected culture. In section 4.2 transient bioproduction, 
the 10mL CD-CHO added post-transfection was supplemented with 7.5%(v/v) final 
concentration of both Efficient Feed A and B (Cat#: A10241-01, Life Technologies). 
 
2.13 Setting up STR Bioreactor 
Stirred tank Bioreactor (STR) fed-batch study was performed in Applikon 1L total volume 
Minibioreactors using myControl Controllers. The impeller used was a marine impeller 
mixing at 170rpm. All gas inlet/outlets are fitted with 0.22µm Midisart® 2000 PTFE vent 
filters (Cat#: 17805, Sartorius AG, Goettingen, Germany), with one of the air outlet through 
a water cooled condenser to avoid water precipitation on the vent filter.  The dissolved 
oxygen (dO2) and pH probes were calibrated using two point calibration. pH was calibrated 
with pH4 and 7 standards. dO2 probe was calibrated in the culturing medium (CD-CHO) 
with 0% dO2 set by sparging pure N2 gas at 0.2L min-1 for at least 1 hr to displace all dO2, 
100% dO2 is achieved through sparging clean air at 0.5L min-1 for at least 1 hr. The set-point 
for pH is at 7 and controlled by CO2 gas addition when above set-point and the addition of 
0.5M NaHCO3 when pH fell below set-point. The set-point for dO2 is at 40% with constant 
addition of 20mL min-1 clean air, it is controlled by addition of N2 gas when above set-point 
and with pure O2 gas below set-point. The bioreactor is also fitted with a sampling line. 
Samples were taken by spraying 80% ethanol on the sampling port and 5mL of culture is 
drawn with a sterile luer-lock syringe (Cat#: 309604, BD Biosciences) and discarded to 
remove old culture within the sample line. A new syringe was then attached and collected 
1.5mL of culture for cell counting.  
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3. Identification of Host Cell Engineering Target 
The translation and secretion bottleneck has often been regarded as the rate-limiting step 
in protein production. We seek to describe the expression level of translation/secretion 
related gene targets and their correlation with productivity. In this study, we have selected 
several monoclonal antibody (mAb) producing cell lines with a wide range of productivity 
and characterized their gene expression level of several key ER/Golgi resident proteins 
using quantitative PCR (qPCR) and examined each gene targets’ correlation with cell 
specific productivity. The mAb producing clonal cell lines were kindly provided by the 
National Biologics Facility for characterization. 
 
3.1 Characterization of mAb producing clones (Growth and Productivity) 
The mAb producing cell lines employed in these studies are derived from a suspension 
CHO-K1 line named CHO-XL99. The CHO-XL99 parental cell line was derived from the 
original adherent ATCC-61 cell line and then subsequently adapted to suspension growth in 
chemically defined medium. Briefly, the parental CHO-XL99 was stably transfected with the 
cDNA of IgG4 mAb called 3C12. The cDNA was inserted into a single expression vector 
system which also included the Glutamine synthetase (GS) and puromycin resistance gene 
as markers for selection. The transfection was performed using electroporation and cells 
were split into two groups for selection of resistant cells. The first group of cells were seeded 
directly from chemically defined (CD) medium supplemented with 10 µg mL-1 of puromycin. 
Based on previous experiments, at 10 µg mL-1 of puromycin, we were able to select cells 
which have the expression vector stably integrated into the genome.  This bulk selection 
process generated a resistant population consisting of a heterogeneous population of cells 
expressing at different levels of mAb, followed by a semi-solid phase method for clonal 
isolation. Bulk selection and mini-pool selection methods are commonly used in industry. 
However, in an effort to isolate mammalian cell lines with manufacturing desired traits, an 
optimized semi-solid method was also employed to generate further clones. Thus, a second 
group of transected cells were used as a direct inoculum for seeding into the semi-solid 
CHO-G medium for clonal isolation. All clones were isolated using ClonePix FL based on 
their inferred productivity from fluorescent intensity. For a comparative analysis, clones C1-
C5 were isolated using the conventional approach while clones C6-C10 were isolated 
through a single-step semi-solid method. Further details on the generation of mAb producing 
clones can be found in Section 2.2.  
 
39 
 
All clones were cultured in 10mL of CD-CHO in 50mL vented cap bioreactor tubes as batch 
cultures, i.e. no additional feeding strategies used. The initial seeding density was 1x106 
cells mL-1, growth curve and productivity data (cell specific and total product titer) were 
collected on Days 1, 2, 3, 4, 7 and 10. Cell density and viability was determined using trypan 
blue exclusion on an automated cell counter Cedex HiRes and data presented in Figure 5. 
Total product titer was determined using sandwich ELISA as described in Section 2.3. We 
also explored two different methods of determining qp; the conventional method, where the 
change in total mAb accumulation is divided by the integral of viable cells (calculation 
formulae described in Section 2.4) and cell surface staining of secreting mAbs. The cell 
surface staining method was adapted from methods previously described by Brezinsky and 
Pichler [134, 135]. Briefly, this method stains the recombinant IgG while they are still 
embedded on the cell surface during secretion with a detection antibody conjugated to a 
fluorophore, which in our case is Allophycocyanin (APC). Once stained, the cells are then 
measured using flow cytometry to quantify the intensity of APC on the cell surface. The 
fluorescent intensity would then be a function of qp and this method of qp quantification is 
compared with the conventional method by drawing correlation between the two methods. 
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Figure 5. Growth and Viability of mAb producing clones. 
The graphs depict the growth curve and viability for 10 mAb producing clones isolated using two different 
methods. C1-5 was isolated from direct seeding and selection in semi-solid medium, while C6-10 were isolated 
using a conventional approach where a resistant pool was generated prior to seeding into semi-solid medium. 
Clones were grown in 10mL CD-CHO medium with no supplements in 50mL vented bioreactor tubes. The 
initial seeding density is at 1x106 cell mL-1 in batch mode where no feeding strategies were adopted. Cell 
density and viability were determined using trypan blue exclusion on automated cell counter, Cedex HiRes. 
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Figure 6. Productivity of mAb producing clones. 
The total product titer and cell specific productivities (qp) were determined for all clones. Culture samples were 
centrifuged to remove cells and cell debris and supernatants were collected to determine the product titer using 
sandwich ELISA. The qp for each clone was determined using two different methods, bottom-left and bottom-
right graphs depict the correlation between the two methods used to demonstrate the validity of both methods. 
The first method is determined using the conventional calculation based on the Integral of Viable Cells (IVC) 
as described in Section 2.4, the reported qp is the average qp from Day 2 to Day 7. While the second method 
for qp determination is based on the fluorescent cell surface staining method as described in Section 2.5. 
Fluorescent equivalent value of qp is reported as the Relative Fluorescent Unit (RFU) of APC conjugated to 
the detection antibody. Both methods of qp quantification corroborated with each other as demonstrated by 
their strong correlation at correlation coefficient of 0.833.   
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All clones reached a peak cell density of approximately 5-10x106 cells mL-1 in batch culture 
mode. From the growth data, there is a greater heterogeneity between C6 to C10 compared 
with C1 to C5 as the variability in growth is significantly greater among the 5 clones isolated 
using the single step method clonal isolation method. While further validation experiments 
are required, it is evident that during the 21 days selection process to generate the resistant 
pool, there would be a bias towards cells of similar growth pattern due to the highly 
uniformed cell passaging routine as well as the time required for resistance. Examination of 
the specific productivity showed that there were significant variations in both the product titer 
and the qp. In fact there was a 10 fold difference in product titer on Day 7 ranging from 50 
to 500 mg L-1 while qp ranged from 1.62 pcd to approximately 50 pcd. The diversity in 
specific productivity provides a fascinating group of clones for further analysis*.  
 
*Please note: Clone C5 exhibited high tendency to form aggregates and clump together 
even in the presence of Anti-clumping agent. Therefore C5 is removed from future studies 
due to difficulties obtaining accurate cell count data.  
 
Specifically, samples were collected on Day 10 for productivity assessment, however the 
values used for the calculation of qp were day 7. This is due to the significant drop in cell 
viability past day 7 which will inaccurately affect the calculations on specific productivity. 
Furthermore, calculations on pcd should also be on the maximal cell density during the 
culture period. As such, all clones had reached maximum cell density on day 7 or prior. From 
the selection of clones, Clone C9 exhibited the highest qp at approximately 50 pcd, however 
this is impacted by the slow growth with doubling time at 80.7 hr. It was able to reach a peak 
cell density of 5.5 x106 cells mL-1 on Day 7, however cell viability started to decline following 
this point. Clone C6 exhibited the lowest qp at 1.67 pcd but reached a comparatively higher 
peak cell density at 7.3 x 106 cells mL-1, with an average doubling time of 33.2 hrs. Clone 
C7 showed one of the fastest growth rates, peaking at 11.6 x106 cell mL-1 with doubling time 
of 20.4 hrs but demonstrated comparatively low qp of 6.11 pcd. While cell growth has a 
significant impact on the volumetric productivity, the growth rate is often affected by an array 
of inherent cellular attributes such as metabolic efficiency. As such, variations in growth was 
examined but will not be exploited for host cell engineering in this work, but instead this work 
focusd on the engineering of translation and secretion machinery. 
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3.2 Gene expression analysis of Translation and Secretion Targets in High 
Producers  
Manufacture-ready cell lines with high volumetric productivity often have been isolated 
through a stringent process, where through natural selection a daughter cell has developed 
into a suitable host for a specific protein of interest. Through natural selection, the cell line 
may have developed an extraordinary streamlined molecular pathway to express a high 
level of recombinant proteins. However, as these changes are often rare and random and 
can stem from increased transcriptional to secretion capacities, it is first and foremost 
important to understand the critical quality attributes that ‘nature’ classify as important. In 
order to characterize the translation and secretion machinery of these new cell lines, we 
employed quantitative PCR (qPCR) to examine the gene expression profile for ER and Golgi 
associated gene targets combined with the ER-Tracker staining to evaluate ER size. The 
targeted genes and brief descriptions of their involvement in translation and secretion 
mechanism are summarized in the Table 3. The primer sequences used in qPCR are 
described in Appendix A4; 
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Gene 
Target 
Description 
XBP1-S 
Protein product is a potent transcription factor which up-regulates cytoprotective 
genes upon the induction of UPR. Spliced by IRE1 
XBP1-US Constitutively expressed, the protein product will bind and degrade XBP1-S protein.
BiP 
Binding immunoglobulin protein. ER resident folding protein, also responsible for 
the detection of ER stress. Highly up-regulated during ER stress. 
Calnexin 
Chaperone protein integrated on the ER membrane that specifically binds and 
retains unfolded glycoprotein. Critical in glycoprotein quality control and allows mis-
folded glycoproteins to be retained in ER to re-fold into correct conformation. 
PDI 
Protein disulfide-isomerase 3, catalyzes the formation and breakage of disulfide 
bonds between cysteine residues within proteins as they fold. 
Sec23A 
Part of the coat protein complex responsible for vesicle transport of protein from ER 
to the Golgi. (Component of the COPII coat, that covers ER-derived vesicles 
involved in transport from the endoplasmic reticulum to the Golgi apparatus. COPII 
acts in the cytoplasm to promote the transport of secretory, plasma membrane, and 
vacuolar proteins from the endoplasmic reticulum to the Golgi complex.) 
YKT6 
Involved in protein trafficking between ER and Golgi, part of the SNARE 
superfamily responsible for vesicle fusion. 
EDEM1 
Chaperone protein involved in ER associated degradation. (Extracts mis-folded 
glycoproteins, but not glycoproteins undergoing productive folding, from the 
calnexin cycle. It is directly involved in endoplasmic reticulum-associated 
degradation (ERAD) and targets mis-folded glycoproteins for degradation in an N-
glycan-independent manner, probably by forming a complex with SEL1L. It lacks 
mannosidase activity) 
ATF4 
Activating Transcription Factor 4. Downstream target of the PERK pathway which 
then up-regulates CHOP. 
CHOP 
Also known as DNA damage-inducible transcript 3 protein. Downstream target of 
PERK pathway, down-regulates anti-apoptotic mitochondrial protein Bcl-2. 
Table 3. Summary of translation and secretion markers targeted. 
 
Detailed qPCR protocol is described in Section 2.7. Briefly, 5x106 cells were collected and 
RNA extracted followed by cDNA synthesis using poly-dT primer. The qPCR was performed 
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on Applied Biosystems ViiA™ 7 system for comparative analysis of the relative gene 
expression profiles. The reference cell line used was parental CHO-XL99 and mRNA copy 
numbers were normalized against both GAPDH and Mgat1 housekeeping genes. 
Furthermore, we also used ER-Tracker Green to stain the mAb producing clones followed 
by flow cytometry to quantify the size of the ER. The ER size and the expression level of the 
gene targets provide an indication of the translation and secretion capacity. We then 
examined each gene target for their impact on qp to isolate a target for host cell engineering. 
The results are summarized in Figure 7. 
 
 
Figure 7. Pearson’s correlation coefficient of qp to each translation and secretion indicators from the 
nine mAb producing clones. 
 
Differential gene expression analysis of the mAb expressing cell lines aims to reveal the 
correlation of each translation and secretion related markers to cell specific productivity. We 
used Pearson’s correlation coefficient to draw dependencies between qp and expression 
level of each target. One of the most iconic and most prominent folding proteins, BiP, 
showed no correlation with qp (0.06). This result concurred with previous attempts by Borth 
et al. [123] which showed no improvement in the over-expression of BiP to increase 
bioproduction. Similarly, Calnexin is responsible for folding glycoproteins and PDI, which is 
responsible for the formation of disulfide bonds, also showed minimal, if not slight negative, 
correlation with qp. This is an unexpected result as the assumption would be that folding 
proteins BiP, Calnexin and PDI would have important contributions in cells where there are 
high demands for protein translation and folding. However, the mixed results from the 
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literature on the over-expression of folding proteins (BiP, PDI, Calnexin) does support the 
notion that translation may not be limited [123-125, 127, 130, 132, 136-140]. We then 
investigated the correlation between our secretion markers; YKT6 and Sec23A. YKT6 is a 
member of the SNARE (Soluble NSF Attachment Protein Receptor) protein superfamily 
which is responsible for the recognition and fusion of transport vesicles with other cellular 
membranes including the plasma membrane. YKT6 in particular is a membrane bound 
protein which recognizes and facilitates anterograde transport from ER to Golgi. Sec23A 
forms part of the vesicle coat protein complex and is involved in the vesicle budding for ER 
to Golgi transport. Despite their important roles in protein transport, YKT6 and Sec23A 
demonstrated no correlation to qp, correlation coefficient of 0.05 and 0.12 respectively. This 
may be explained by the highly complicated nature of protein trafficking which involves 
numerous proteins that often rely on complex formation with other secretory proteins. 
Therefore, it may be difficult for any single secretory protein to be solely responsible for the 
impact on qp. The correlation between ER quality control protein EDEM1 and qp 
demonstrated weak positive correlation at 0.46. Therefore, EDEM1 is also discounted as a 
target for host cell engineering. ATF4 and CHOP showed weak to no correlation of qp at 
0.44 and 0.12 respectively. ATF4 has been documented in literature to enhance protein 
production through the dephosphorylation of eIF2α through GADD34, a downstream target 
of ATF4. However, the weak correlation to qp indicated that phosphorylation of eIF2α may 
not be the deterministic factor of productivity. CHOP is thought to induce apoptosis, 
therefore we do not expect CHOP to have a positive correlation with qp which is supported 
by the data. ER size exhibited some positive correlation with qp at 0.51. However, in the 
current work ER size is simply defined by the abundance of the ER membrane, this work 
does not take into account the performance of ER such as the ribosome counts, proper ER 
structure nor the optimal redox potential within the ER for favorable protein folding. It has 
been observed that proper ER structure is critical for functionality [83].  
 
Our primary target for host cell engineering, XBP1-S mRNA displayed a moderately positive 
correlation with qp at 0.59. Although this is the highest correlation observed amongst all our 
cell engineering targets, it is by no means strong enough to justify that it is a suitable target 
for host cell engineering. This moderate positive correlation perfectly explained the mixed 
success rate reported in the literature. But when we examined the correlation of XBP1-US 
mRNA to qp, we observed moderate negative correlation of -0.52. As previously reported, 
XBP1-US has an inhibitory effect on XBP1-S to revert the cells back to homeostasis or 
steady state. The overall inhibitory effect of XBP1-US may explain the moderate correlation 
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of the two XBP1 mRNA splice variants. Therefore, if we examine XBP1 mRNA splice ratio 
using qPCR, where the abundance of XBP1-S mRNA copy number is divided by XBP1-US 
mRNA copy number to indicate the true abundance of XBP1-S mRNA, then we observe a 
strong correlation coefficient of 0.84 as determined using Pearson’s product-moment 
coefficient. This relationship was further emphasized if we consider the correlation between 
XBP1 splice ratio and qp a non-linear relationship and employ a ranked correlation test for 
dependency. As depicted in Figure 8, it seems that the qp rises exponentially with an 
increase in XBP1 splice ratio, and the correlation calculated using Spearman’s ranked 
correlation method is 0.97, a very strong positive correlation. Through understanding the 
basic regulatory mechanism such as the “feedback loop”, in this case the regulatory role of 
unspliced XBP1 protein, there is clear evidence to suggest that enhancing protein folding 
and secretion at the most basic level would require a multi-modal approach, i.e. XBP1 splice 
ratio rather than an assessment of a single protein. 
 
 
Figure 8. Correlations between Cell Specific Productivity and XBP1 splice ratio as determined using 
Spearman’s ranked correlation coefficient. 
3.3 Investigation of XBP1 splicing event using novel XBP1 reporter system 
To further examine the XBP1 splicing event in CHO cells to confirm its activity and kinetics 
in CHO cells, we have created a XBP1 reporter cell line which emits fluorescence upon 
splicing of the XBP1-US mRNA. The splicing event removes 26 nucleotides from XBP1-US 
mRNA which cause a frameshift mutation. We utilized this frameshift mutation to generate 
a reporter system by attaching an out-of-frame GFP at the 3’ end of XBP1-US mRNA 
Sequence. Under normal growth conditions, the recombinant XBP1-US mRNA has a stop 
codon upstream of GFP which prevent its synthesis. During an UPR event, the splicing will 
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cause the stop codon to shift and generate an alternate open reading frame which translates 
an active GFP. This reporter system is summarized in Figure 9 and full vector map and 
sequence are described in Section 2.8 and Appendix A1. We created the XBP1 reporter cell 
line by stably integrating our reporter construct into CHO-XL99 using standard PEI mediated 
transfection followed by stable cell selection using G418. 
 
 
Figure 9. Summary of XBP1 reporter protein which synthesize an active GFP to visualize and quantify 
the degree of XBP1 splicing event. 
 
3.3.1 Confirmation of XBP1 reporter cell line for the detection of XBP1 splicing 
By using this reporter system, we attempted to accurately determine the cellular XBP1 
splicing event in real-time. To validate this system, the XBP1 reporter cell line was titrated 
against increasing concentration of Thapsigargin. Thapsigargin is a non-competitive 
inhibitor of ER Ca2+ ion channel, blocking of the ion channel will disrupt the redox potential 
in the ER, which causes protein mis-folding and thus initiating UPR. The effect of this 
chemical induced XBP1 splicing event was observed through the increase in fluorescent 
intensity with increasing Thapsigargin treatment as depicted in Figure 10. Cell samples at 
each time point was also taken for qPCR analysis of the XBP1 splice ratio for 1µM and 2µM 
thapsigargin treated cells to confirm the correlation between GFP fluorescent intensity and 
XBP1 splice variant mRNA ratio. 
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Figure 10. Time course study of XBP1 reporter cells cultured in titrating concentration of 
Thapsgargin. 
The cells were sampled on at the indicated time points and GFP fluorescent quantified using flow cytometry. 
The RFU indicates the abundance of XBP1 splicing event, the splicing event shifts GFP to become in-frame 
to emit fluorescence. The table depicts the mean GFP fluorescence and the XBP1 splice ratio as determined 
using qPCR. 
  
GFP RFU
XBP1 S/U 
ratio
1uM thaps 
treated
725 1.1
1152 1.2
1506 6.3
1899 17.8
1947 18
2uM thaps 
treated
775 1.4
1122 4
1695 16.3
2242 37.2
2536 35
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The thapsigargin study confirmed that the XBP1 reporter cell line was responsive to the 
IRE1 splicing of XBP1 mRNA during chemically induced UPR (Figure 10). The amount of 
GFP fluorescent intensity increased with increasing thapsigargin concentration and 
treatment duration. XBP1 splicing increased rapidly during the first 8 hrs of treatment, the 
amount splicing activity started to slow down past the 24 hrs time point. The 0.5µM 
thapsigargin treatment demonstrated a decrease in XBP1 splicing activity after the 24 hrs 
time point which may indicate that the cells had successfully mitigated ER stress and are 
attempting to revert back to steady state. When we compared the XBP1 splice ratio as 
determined using qPCR and that of the GFP fluorescent intensity, the correlation coefficient 
was 0.94 which indicated very strong positive correlation. This result confirmed that we can 
utilize the XBP1 reporter cell line to further understand the kinetics of XBP1 splicing during 
transient bioproduction. 
3.3.2 Investigation of XBP1 splicing event during transient bioproduction 
In this experiment we aimed to further understand the role of XBP1 splicing during ER stress 
induced by the increase in protein synthesis demand, such as that experienced during 
transient bioproduction. The introduction of plasmid DNA encoding an antibody will increase 
the burden on the cellular translation and secretion machinery leading to UPR. With our 
XBP1 reporter cell line, we can study the kinetics of XBP1 splicing during transient 
bioproduction and its relationship with qp. We transfected the XBP1 reporter cell line with 
mAb 3C12 and measured XBP1 splicing activity by GFP fluorescent intensity and qp using 
cell surface staining of secreting IgG. Briefly, 1x106 cells mL-1 was transfected with 1.5µg of 
plasmid DNA using PEI and sampled daily over the course of five days. We also measured 
the gene expression level of BiP, Calnexin, ATF4 and CHOP using qPCR.  
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Figure 11. Summary of result of XBP1 splicing correlation with Transient transfection. 
A. Time course study examining the relationships between XBP1 splicing activity and qp post-transfection. 
CHO XBP1 reporter cell line is transfected with 1.5µg plasmid DNA per 1x106 cells using PEI mediated 
transfection. XBP1 splicing is measured by GFP fluorescent intensity and qp is determined using cell surface 
staining of IgG with APC conjugated detection antibody. B. Correlation coefficient of gene expression level of 
selected targets with qp. C. Correlation coefficient of gene expression level of selected targets with qp when 
staggered by one day, i.e. Expression level of gene targets is aligned with the next day qp value. 
 
The time course study revealed that XBP1 splicing activity and qp follows a very similar 
trend, albeit the trend of the qp response curve was shown to have staggered by one day. 
We believe that this is due to the increase in translation and secretion capacity conferred by 
the increase in XBP1-S, hence the further increase in qp. While often the process of protein 
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expression is cell line dependent, generally, the process of protein expression is divided into 
a number of stages, i.e. upstream stages from transcription, translation to downstream 
stages such as protein maturation and secretion. The delay in the APC (as a detector for 
the secreted protein) data suggests the time required to visualize the effects of an upstream 
change on a downstream target. With this in mind, examining the trends in both the upstream 
and downstream targets, i.e. splicing event and secreted antibody, shows a strong positive 
correlation coefficient of 0.93. The gradual decrease of qp and XBP1 splicing during the time 
course may be due to dilution effect from cell growth. As the cells divide, the daughter cells 
no longer carry the plasmid DNA or GOI and therefore should not experience ER stress and 
the subsequent XBP1 splicing event. However, the concurrent gradual decrease of both qp 
and XBP1 splicing does suggest that the cells constitutively expressing a complex 
recombinant protein may continue to require XBP1 splicing. Therefore, XBP1 splicing, or 
more accurately, the presence of XBP1-S is critical for the synthesis and secretion of mAb. 
When we continue to examine the correlation of BiP, Calnexin, ATF4 and CHOP, no 
significant correlations in trends were observed (Figure 11B) even if we introduced the same 
delay when examining the data (Figure 11C). This suggests that the expressions of these 
gene markers are highly variable and may not have a direct impact on qp, however further 
markers maybe required to examine secondary effects on qp. 
 
3.4 Conclusion 
In this work, we examined a number of translation and secretion associated gene markers 
on the specific productivity of cell lines expressing or producing a recombinant protein of 
interest. The hypothesis centered on the need to further elucidate the role of spliced XBP1 
and its response to UPR. Initially, we selected nine antibody producing clonal cell lines with 
significant heterogeneity based on qp. These clones were characterized based on the 
expression profile of the gene markers and then examined their correlation to qp. We 
concluded that, at best, our gene targets, which included characterized targets from 
translation to secretion, demonstrated only moderate positive correlation to qp. The lack of 
strong correlation with qp was in line with the mixed success rate in the literature on 
translation and secretion engineering to improve recombinant protein production in 
mammalian systems. This further illustrates the complexity of mammalian systems and the 
need to examine the system using a multi-modal approach as process bottlenecks such as 
translation and secretion machinery are governed by a number of upstream and 
downstream markers. For example, protein transport requires hundreds of different proteins 
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at different stages of transport from packaging, coat proteins, docking/recognition protein 
and fusion proteins. Therefore, through examining the mechanisms involved in protein 
folding and secretion and the UPR, we focused our efforts on a global transcription factor, 
such as XBP1-S which is responsible for the regulation of a multitude of cellular functions. 
However, the literature also reported inconsistency when adopting XBP1-S as a cell 
engineering approach, this also coincides with our observation of moderate positive 
correlation with qp. Through the work presented, we conclude that this is due to the fact that 
the role of XBP1-US may have been overlooked and thus resulted in the overestimation of 
XBP1-S expression. As previously mentioned, the constitutively expressed XBP1-US will 
bind to XBP1-S which forms a complex that is subsequently ubiquinated and consigned to 
degradation. This constant removal of newly synthesized XBP1-S protein can significantly 
reduce its effectiveness and effect on downstream targets. This was demonstrated in the 
moderate negative correlation of XBP1-US to qp. Upon consideration of both spliced and 
unspliced XBP1, i.e. the correlation of XBP1 splice ratio to qp, we were able to identify a 
strong positive correlation. This would be the first time, as far as we know, that the XBP1 
ratio has been identified as a potential determinant of qp. As such we believe that XBP1 
ratio is the true indicator of XBP1-S level as the ratio accounts for the inhibitory effect of 
XBP1-US. With this understanding, we proceeded to create a CHO reporter cell line capable 
of demonstrating XBP1 splicing activity in real-time. This reporter system utilizes the 
frameshift mutation incurred during XBP1 splicing to quantify the splicing ratio as a function 
of fluorescence. We then adopted this reporter system in transient bioproduction to examine 
the impact of XBP1 splicing on qp. Our results indicated the trend in qp and level of XBP1 
splicing showed a strong correlation. The strong positive correlations between qp and XBP1 
splicing warranted further investigation into its validity as a target for host cell engineering 
of the translation and secretion machineries. Therefore, we propose that the over-
expression of XBP1-S alone is not sufficient to generate a host cell but rather a further 
process of selection or gene characterization is required to reveal the true downstream 
effects from the over-expression of an upstream target. The subsequent host cell line will 
then become an ideal platform to improve both transient and stable bioproduction. 
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4. Validation and Proof-of-Concept for XBP1 Host Cell Line 
In our previous work, we have confirmed the critical involvement of XBP1 protein in 
challenging the limits of recombinant protein expression in a mammalian system. However, 
XBP1-S needs to be at sufficient abundance to overcome the inhibitory effect of XBP1-US, 
and this was supported by the strong positive correlation between qp and XBP1 splice ratio 
as opposed to the moderate correlation when XBP1-S was considered independently. 
Therefore we will continue to examine XBP1 splice ratio as our strategy for host cell 
engineering. To facilitate this strategy and further understand the impact of XBP-S as a host 
cell engineering target, it is essential that we first create a new host CHO-XL99 cell line over-
expressing the XBP-1 protein prior to the introduction of the gene of interest. By 
incorporating the XBP-1, we hypothesize that the activation of the XBP1 specific pathway of 
the UPR will enhance the survivability of the transfected population as the cells experience 
higher levels of protein expression related stress. This will subsequently result in a greater 
diversity within the resistant population during cell line generation which will become an 
advantage during clonal isolation. This concept of higher quality population post-transfection 
is also applicable in transient bioproduction where ER stress would also be a critical 
challenge to overcome at higher volumetric productivities.  
 
In the current chapter, we will create our high XBP1 splice ratio host cell line (henceforth 
referred to as XBP1 cells) and conduct a proof of concept study in transient bioproduction. 
In our proof of concept work, we’ve opted to conduct all cell culture work in a basal medium 
such as DMEM/F12. However, it is difficult to culture suspension cells in such basic medium, 
therefore we employed similar basal medium such as CHO-SFMII (Life Technologies). The 
reason behind adopting basal medium in our proof of concept study is that we believe it will 
be easier to identify potential cell line deficiencies in basal medium such as CHO-SFMII. In 
particular, we are concerned with the potential masking of cell stress due to the presence of 
growth factors in highly optimized medium. 
 
4.1 Creation of XBP1 host cell line 
In order to generate our XBP1 host cell line, we will require a method to identify high XBP1 
splice ratio cells. To achieve this, we have used a bicistronic vector system co-express the 
XBP-1S protein as well as GFP. The XBP-1S cDNA is 5’ of the GFP cDNA with the two 
coding sequences separated by an internal ribosomal entry site (IRES). As both genes are 
subsequently expressed off the same promoter, the level of GFP is proportional to the level 
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of XBP-1S expressed. By using flow cytometry, the high XBP1-S expressing cells are (i.e. 
high GFP population) are enriched and then further characterize XBP splice ratio using 
qPCR. For the purpose of understanding the impact of XBP-1S based cell engineering, it 
will be critical to have sufficient heterogeneity and diversity within the population. Thus, only 
cells expressing high GFP were collected with FACS to create this enriched population. As 
we hoped to develop a platform cell line which can be used in the bioproduction of various 
therapeutic proteins, it is important that diversity is maintained in the host cell line to avoid 
protein dependent effects. In an effort to develop a more efficient system for bioproduction 
platforms, it is important to maintain the population heterogeneity, until such time that there 
is sufficient understanding in the effect of XBP1 protein, prior to host cell line isolation from 
this population.  
 
CHO XBP1-S sequence was derived from endogenous CHO-XL99 XBP1-S mRNA. This 
sequence was cloned into in-house bicistronic vector with attenuated Internal Ribosome 
Entry Site (aIRES) followed by GFP. The XBP1-S sequence was inserted upstream of the 
aIRES site and the full vector map is described in Section 2.10 and Appendix 2. The 
incorporation of aIRES-GFP allows for the identification of cells expressing the recombinant 
XBP1-S but without incurring too much addition ER burden from the synthesis of excess 
eGFP. The cells are then selected with 8µg mL-1 final concentration of Puromycin and 25 
µM of MSX (methionine sulfoximine). The resistant pool was then sorted using the BD FACS 
Aria IIIu cell sorter and deposited into DMEM/F12 supplemented with 10% Fetal Bovine 
Serum. Figure 12 depicts the population diversity of the original resistant XBP1 cells (A), the 
sorted cells grown in DMEM/F12+10% FBS (B) and the population diversity of enriched 
XBP1 cell line (C). The enriched XBP1 cell is then characterized for the expression level of 
translation and secretion gene markers. 
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Figure 12. Cell sorting of XBP1 resistant pool. 
A. Population profile of XBP1 resistant pool after 21 days in selection. Cells are expressing CHO XBP1-S in 
bicistronic vector with aIRES GFP. P4 indicates the gate used to sort out cells with high XBP1 expression (high 
GFP). Prior to sorting there was 3.8% of the population in P4. The sorted cells were deposited in DMEM/F12 
with 10% FBS. B. Sorted high XBP1 (GFP) expressing cells recovering in adherent culture grown in 
DMEM/F12 with 10% FBS. C. After recovery post sorting, the cells were cultured in suspension culture with 
CHO-SFMII medium. The cells were re-analyzed with flow cytometry and demonstrated enrichment of the 
population. P4 now accounts for 40% of the population.  
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4.2 Characterization of improved host cell 
The XBP1 cell line was characterized using qPCR to examine the relative changes in its 
translation and secretion gene expression as compared to the parental CHO-XL99 cell line 
(Figure 13A). The subsequent expression profiles confirmed a higher XBP1 splice ratio of 
1.54 as determined by dividing XBP1-S mRNA copy number by XBP1-US mRNA copy 
number. Protein markers often associated with the apoptotic arm of UPR such as ATF4 and 
CHOP were at baseline level. Chaperone proteins such as BiP and PDI were found to 
increase by 1.18 and 1.82-fold respectively. ER to Golgi transport protein such as Sec23 
was increased by 2.7-fold. Finally, EDEM1, responsible for binding and degrading mis-
folded glycoproteins was also up-regulated by 2.34-fold. As a comparison, Figure 13B 
illustrates the gene expression profile of CHO-XL99 treated with 1µM thapsigargin for 24hrs 
to chemically induce UPR. Thapsigargin treatment exhibits canonical UPR, the apoptotic 
markers ATF4 and CHOP were significantly up-regulated, 7.6 and 31.8-fold increase 
respectively. While the XBP1 splicing was also activated as demonstrated by the notable 
increase in XBP1-S combined with the near absence of XBP1-US, other representative 
downstream targets of UPR were also up-regulated; BiP (15.5-fold increase), PDI (4.1-fold 
increase) and YKT6 (4-fold increase). This was also accompanied by phenotypic changes 
such as a significant slowdown in growth and a decrease in cell viability. From this result, 
we are able to establish the differences in gene expression profiles between the XBP1-S 
mediated response and the full activation of all three UPR pathways. Activation of XBP-S 
modulated UPR results in cellular changes to counteract the presumed stress from the 
microenvironment, progression down the other pathways; ATF and CHOP would result in 
cellular apoptosis. Therefore it is critical to create a host cell line with selective activation of 
XBP1-S pathway to improve the cytoprotective effects of UPR rather than apoptosis. 
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Figure 13. Characterization of XBP1 cell line for translation and secretion associated marker 
expression with qPCR. 
A. The graph depicts the expression profile of XBP1 host cell line under routine culturing, sample taken 48 hrs 
post-passaging. The result was reported as fold change over CHO-XL99 cell line normalized with reference 
genes GAPDH and Mgat1. The XBP1-S mRNA includes both the endogenous and recombinant form of XBP1-
S. The growth rate of the XBP1 host cells was similar to that of CHO-XL99, while the apoptotic markers (CHOP 
and ATF4) were expressed at baseline levels. B. As a comparison, this graph depicts the gene expression 
profile of CHO-XL99 cell line treated with 1µM of Thapsgaragin for 24hrs to chemically induce UPR. The 
chemical induction of UPR is non-selective and will trigger all three UPR pathways as evident in the strong up-
regulation of apoptotic markers CHOP and ATF4. 
 
4.3 Transient transfection study in XBP1 cell line 
In order to examine the suitability of XBP1 cell line in mAb production, we compared our 
XBP1 cell line to CHO-XL99 as transient production host. The XBP1 cell line exhibited higher 
XBP1 splice ratio (1.54 fold increase), which we found to have the highest correlation to qp. 
Our gene expression profiling also demonstrated that we have selectively activated the 
cytoprotective arm of UPR with increased translation and secretion associated gene 
expression while maintaining baseline expression apoptotic related genes. In this section, 
we will evaluate the performance and output of XBP1 cell line against CHO-XL99 in mAb 
transient bioproduction.  
 
4.3.1 Effects of plasmid DNA titration on XBP1 cell line 
In this experiment, we investigated the qp of both cell lines with increasing amounts of 
plasmid DNA used for transfection, we assume that the increase in plasmid DNA will equate 
to increased GOI mRNA copy number. Cells were transfected with a single 9.7Kb plasmid 
DNA encoding both heavy and light chain of 3C12 mAb. We hypothesize that by increasing 
59 
 
the plasmid copy number, it will also increase the translation/secretion burden on the cells. 
As such, XBP1 cell line with the enhanced cytoprotection would have a greater advantage 
in processing the translation demand resulting in higher cell specific productivity. To 
investigate the effect on qp with plasmid titration, we collected the cells 48hrs post-
transfection and conducted cell surface staining of secreting IgG to estimate the qp. While 
volumetric productivity measurements are preferred over specific productivity when 
examining the efficiency of transient bioproduction, we find that qp is a more useful indicator 
of a cell line’s translation and secretion performance. The results revealed that at 1µg 
plasmid DNA per 1x106 cells, there was no observable difference in qp between the two cell 
lines. However, as we increased the amount of plasmid DNA to 1.5µg and 2µg, we observed 
that the qp of XBP1 cell line was 26.6% and 47.5% higher than CHO-XL99 (Figure 14). This 
observation supports the hypothesis that, by expanding the host cells’ folding and secretion 
capacities, it would allow the cells to process greater translation demand, thus assist in 
alleviating the translation/secretion bottleneck. The differences observed in qp through 
incremental increase in plasmid copy number suggest that the over-expression of XBP-1S 
does have a positive effect on recombinant protein expression. For highly complex proteins 
such as mAbs, it would be reasonable to suggest that the rate-limiting step will gradually 
shift from transcription towards translation and secretion with increasing plasmid copy 
number. Here we have demonstrated that a cell line which possesses augmented translation 
and secretion machinery is more ideal as a production host under conditions of high ER 
stress such those experienced during transient bioproduction. 
 
 
Figure 14. The graph depicts the effect of titrating amount of plasmid DNA on qp between CHO-XL99 
and XBP1 cell line. 
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The graph is presented as percentage difference in qp of XBP1 cell line over CHO-XL99. The transfection 
was performed with PEI mediated gene delivery in CHO-SFMII. The qp was estimated using cell surface 
staining 48 hrs post-transfection. 
 
4.3.2 Transient batch productivity study 
Following this, we performed a batch transient production study using PEI to validate the qp 
and volumetric productivity using 2µg of plasmid DNA per 1x106 cells mL-1 (Figure 15). The 
plasmid DNA used for the transient batch production was single plasmid encoding 3C12 
mAb, and the production was performed in CHO-SFMII (transient transfection method is 
described in Section 2.12). The final volumetric productivity on Day 7 was higher in XBP1 
cultures compared with CHO-XL99; 5.1 versus 4.4 mg L-1. However, the growth rate of XBP1 
cell line was significantly slower than CHO-XL99, the XBP1 cell line reached peak cell 
density of 1.93x106 cell mL-1 as opposed to 3.1x106 cells mL-1 achieved by CHO-XL99 on 
Day 7 with similar cell viability. These results indicated a significant difference in the qp 
between the two cell lines; XBP1 cell line demonstrated an 87.5% increase in average qp 
over CHO-XL99 control cell line. It is interesting to note that despite the enhancement in 
folding capacity through the over-expression of XBP1 protein and subsequently the 
activation of UPR, no significant growth advantages was observed. While the viability post 
transfection was comparable, cell growth was significantly slower in XBP1 cell line as 
compared to CHO-XL99 cells post-transfection. Moreover, gene expression profiling of the 
cells post-transfection revealed that UPR specific apoptotic marker such as CHOP [28-31] 
was higher in the XBP1 cells compared to CHO-XL99. This led us to conclude that the 
selective activation of XBP1 pathway may not be sufficient to reduce the apoptotic response 
from other UPR components. Thus, the elevation of CHOP from the transfection process 
illustrates that the constitutive over-expression of XBP1 assists in qp but does not prevent 
cells from undergoing apoptosis.   
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Figure 15. Summary of result from Transient Bioproduction in CHO-SFMII. 
A. The mAb volumetric productivities of XBP1 cells were assessed. The graph depicts the time course 
accumulation of secreted mAb between XBP1 and CHO-XL99 cell lines as determined by sandwich ELISA. B. 
The cell growth curves post-transfection was recorded by using Cedex HiRes. 
 
Despite not being able to reduce UPR induced apoptosis from the selective activation of 
XBP1 pathway, we still observed significant improvement in qp and overall increase in 
volumetric productivity. It is understood that bioprocess optimizations can improve the 
overall productivity, therefore we will perform a more advance study in the later chapter to 
explore the performance of our XBP1 cell line in highly optimized culture medium such as 
CD-CHO and with the necessary feeding regimes in an industrial setting. 
4.3.3 Genetic regulations post-transfection in XBP1 cell line 
As indicated previously, the transient production results demonstrated notable differences 
in the qp between the two cell lines. Therefore, apart from apoptotic markers, we also 
examined both cell lines using qPCR, to further understand the differential expression of 
genes related to the UPR. The results are presented in Figure 16.  
 
 
 
      A              B 
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Figure 16. Gene expression profiling of XBP cell line and CHO-XL99 post-transfection. 
ER and UPR associated gene expression post-transfection was investigated to compare CHO-XL99 and 
XBP1 cell lines. Cells were collected 48hrs post-transfection and their gene expression assessed using 
qPCR. The results were expressed as fold change in mRNA abundance normalized to respective 
untransfected samples. GAPDH and Mgat1 were selected to normalize template abundance. A. CHO-XL99 
cell line post-transfection. B. XBP1 cell line post-transfection. C. XBP1 cell line post-transfection normalized 
to untransfected CHO-XL99..  
 
Firstly, the qPCR revealed numerous changes between transfected and untransfected CHO-
XL99 in terms of ER and UPR gene regulation (Figure 16A). The influx of translation demand 
from the plasmid DNA triggered differential expression of UPR-related genes and initiated 
XBP1 splicing, thus elevating the XBP1 ratio to 1.67 in CHO-XL99 and 3 in XBP1 cell line. 
As a result, XBP1-S downstream targets were up-regulated, expression of folding proteins 
Calnexin and PDI increased along with transport proteins Sec23, YKT6 and quality control 
protein EDEM1. Apoptotic markers, CHOP and ATF4, were also elevated as a result of the 
transfection process. Collectively, the elevation of apoptotic markers suggests that the cells 
are overwhelmed by the process, while cells have been efficiently transfected, subsequent 
ER stress directly impact on cell growth and thus volumetric productivity.   
A B
C
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There were surprisingly minimal changes in folding and transport protein expression 
between transfected and untransfected XBP1 cell line (Figure 16B). The presence of 
recombinant XBP1-S coupled with elevated endogenous XBP1 splicing increased the XBP1 
ratio to 3. When the transfected XBP1 cell line was normalized against the untransfected 
CHO-XL99 cell line (Figure 16C) it was revealed that all ER/UPR targets were significantly 
higher compared to transfected CHO-XL99. This may be explained that the recombinant 
XBP1-S expressed by the XBP1 cell line has already up-regulated its downstream targets.  
 
Consequently, the increase XBP1 ratio achieved through IRE1 splicing of endogenous 
XBP1 yields no further up-regulation of the downstream targets. Both ATF4 and CHOP were 
up-regulated indicating that both cell lines are experiencing ER stress. The increased 
expression of chaperone and secretory proteins prior to transfection did not prevent XBP1 
cell line from triggering apoptosis. As ATF4 and CHOP were regulated by the PERK pathway, 
it seems that XBP1-S has minimal impact on PERK mediated apoptotic response.  
 
Even with the constant presence of XBP1-S in host cells, an important protein folding marker; 
BiP was not observed to be significantly up-regulated. From literature, previous studies as 
well as our own correlation studies we were unable to demonstrate any correlation between 
BiP and mAb production. Nevertheless, BiP remains critical in the activation of the PERK 
pathway which leads to ATF4 and CHOP expression. The limited BiP up-regulation implies 
that XBP1 cells are not resistant to PERK activation and its downstream apoptotic markers 
activation, ATF4 and CHOP [28-31]. This seemed to be also supported by the observed 
slower growth of XBP1 cell line post-transfection. 
4.3.4 Change in expression heterogeneity. 
One of the initial hypotheses was that the use of XBP1 cell line can generate a higher “quality” 
resistant pool. We define resistant pool “quality” as the number of high expressing cells 
within the transfected population. The simple advantage of having a higher percentage of 
high producers becomes apparent during the clonal isolation step of cell line development 
where thousands of clones need to be screened to isolate a suitable line for manufacturing. 
Therefore to identify this advantage, it is important to compare the population distributions 
of mAb producing cells between the two post-transfection populations using cell surface 
staining and flow cytometry. Following transfection (48 hr), cells were stained against 
secreting mAb on the cell surface and analyzed using flow cytometry. The population 
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distributions of antibody expressing cells are shown in Figure 17. We designated an arbitrary 
gate at ≥104 relative fluorescent units (RFU) to define any cells observed above this gate as 
high producing cells. The results showed that there were three times more high producing 
cells in the XBP1 transfectants compared to CHO-XL99. With 18.8% of XBP1 cells included 
in the high producer gate, compared with only 6.1% of transfected CHO-XL99 cells beyond 
this gate. This increase in probability was also corroborated by a significant shift in 
fluorescence median from 1201 RFU in CHO-XL99 to 2902 RFU in XBP1 cell line. These 
results suggest that XBP1 mediated augmentation of host cell line can increase the 
probability of isolating high producers by increasing the output of the entire population. Thus, 
instead of an extensive clone screening regime, with this XBP1 cell line we are able to 
improve the survivability (increasing the number of high producers which would normally 
succumb to high ER stress) of cells post-transfection and selection, consequently offering a 
larger population of high producers for screening. 
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Figure 17. Graph depicting the population distribution of transfected cell qp. 
48hrs post-transfection, fluorescent immunostaining was performed on CHO-XL99 and XBP1 cells to assess 
their qp population distribution. 20,000 single viable cells were collected for qp histograms, a high producer 
gate was set at RFU of ≥104. Top. CHO-XL99 population distribution; Mean: 3842 Medium: 1201 CV%: 373.9 
High producer population: 6.1% Bottom. XBP1 population distribution; Mean: 6993 Medium: 2902 CV%: 227.3. 
High producer population: 18.8%. 
 
4.4 Conclusion 
There have been numerous attempts to improve bioproduction using XBP1-S, but the results 
of these studies remained inconsistent. While there have been noticeable improvements for 
proteins such as erythropoietin and SEAP, the same could not be said for large multi-subunit 
proteins such as mAbs. In our proof of concept study, we have shown that through our 
XBP1-S engineered host cell line, we can significantly increase the specific productivity for 
mAbs while also increasing the probability of isolating a high producer through an 
enhancement in increased selection survivability.  
 
In the previous chapter, our data revealed that the cell specific productivity correlates 
strongly with increasing ratio of spliced over unspliced XBP1. XBP1-US has been reported 
to act as the negative regulator of XBP1-S to revert the cell back to steady-state after the 
successful mitigation of UPR. In the current study, we attempt to increase the probability of 
isolating suitable production cell lines by enhancing the cellular translation and secretion 
machinery to over the perceived bottlenecks through rational host cell engineering of the 
XBP1 ratio. Through the use of a bicistronic vector construct expressing CHO XBP1S with 
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downstream attenuated IRES followed by GFP, this construct provided the possibility of 
identifying and isolating cells with possible high XBP1 splice ratio due to the co-expression 
of GFP. The attenuated IRES were also used to modulate the level of GFP thus removing 
any unnecessary protein synthesis burden on our host cell line. Characterization of the 
XBP1 host cell of their ER and UPR associated gene expression confirmed that our XBP1 
host cell line does exhibit the higher XBP1 splice ratio phenotype. The high XBP1 splice 
ratio signifies the excess of XBP1-S protein which will be available to overcome the inhibitory 
effect of XBP1-US as well as the selective activation of the XBP1 branch response. This 
was further supported by the increase in differential expression of genetic markers involved 
in protein folding, secretion and quality control. Furthermore, it was encouraging to identify 
that there was a significant elevation in XBP1 ratio independent of the apoptotic markers.  
 
XBP1 cell line demonstrated significantly higher specific productivity, especially under high 
concentration of transfected plasmid which would have challenged the translation capacity 
of both cell lines. We observed increasing outperformance of XBP1 cell line over CHO-XL99 
under increasing translational pressure. This was further validated in our transient batch 
production when we compare both qp and final volumetric productivity. The XBP1 cells were 
observed to have a moderate increase in final titer, however the growth rate was noticeably 
slower post-transfection. This suggested that the XBP1 cell line suffered cellular stress 
which impacted on its proliferation rate, but the high qp was sufficient to compensate for the 
reduced growth. Subsequently, we employed qPCR to examine the gene expression profile 
of XBP1 cell line during transient bioproduction to further elucidate the mechanics of the 
reduced cell growth and higher qp. It was surprising to witness minimal increases in 
translation and secretion related proteins when comparing transfected XBP1 cells against 
the untransfected XBP1 cells. Our explanation was that under unstressed conditions, XBP1 
cell line with its high XBP1 splice ratio possesses freely available XBP1-S transcription factor 
to up-regulate its downstream targets despite not experiencing UPR. Consequently XBP1 
cells had already saturated its XBP1 target expression, leading to minimal increase in target 
expression post-transfection. The gene expression analysis also revealed that the 
augmentation of translation and secretion machinery via XBP1 up-regulation was not 
sufficient to counter the apoptotic effects of other UPR components such as CHOP induced 
apoptosis post-transfection. We suspected that this may be due to the limited up-regulation 
of BiP in XBP1 cell line. As both ATF4 and CHOP, downstream targets of PERK require the 
association with BiP for inactivation [20, 21, 35].  
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When we investigated the population distribution of transfected XBP1 cells, it was 
encouraging to witness a noticeable shift towards high producers. We observed a 3-fold 
increase in the percentage of high producers. This was also supported by significant 
increase in population mean and medium. This increase in percentage of high producers 
should translate into higher quality resistant pool which is comprised of higher proportions 
of high producing cells. High quality resistant pool can drastically reduce the number of 
clones required to screen to obtain a production cell line, thus simplifying the cell line 
development process [112, 113].  
 
In conclusion, through target screening and correlation studies from the mAb production 
lines in the previous chapter, we were able to successful create a unique cell line with high 
XBP1 splice ratio. This cell line overcame the inhibitory effect of the XBP1-US, 
demonstrating higher translation and secretion gene expression. We also demonstrated 
compelling evidence that our enhanced cell line is a more suitable host cell line for mAb 
bioproduction over parental CHO-XL99. This was exemplified by the significant increase in 
qp during transient bioproduction. However, the XBP1 cell line exhibited slower growth rate 
than CHO-XL99 leading to only moderate increase in volumetric productivity, this can often 
be overcome by further bioprocess optimization achievable due to the inherent cellular 
plasticity of CHO which will be examined in the subsequent chapter.  
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5. Industrially Relevant Application of XBP1 Host Cell Line 
XBP1 splice ratio has proved to be a viable target to modify the host cell for transient and 
stable bioproduction by significantly increasing the qp and the probability of isolating high 
producers. Our work thus far has been performed in simple medium with minimal 
optimization for bioproduction, but in this chapter we will be focusing beyond protein 
expression and adopting the idea of protein manufacturing. The level of sophistication with 
the bioprocess approach has evolved the industry over the last 20 years. As regulators 
continue to review and update approval guidelines, the standards for bioproduction will also 
require to keep pace, one good example is the shift towards chemically defined medium to 
reduce batch to batch variability. The low peak cell density and slow growth rate witnessed 
in the XBP1 cell line may be inadequate for industrial use, therefore, in this chapter we will 
consider modern bioprocess optimization such as transition into chemically defined medium, 
feeding regimes. Specifically, we will revisit our transient bioproduction in chemically defined 
medium with optimized feeding strategy. We will also create mAb producing resistant pool 
and assess the quality of our resistant pool. Finally, we will assess the scalability of the 
XBP1 cell line in stirred-tank (STR) Bioreactor to examine both cell growth and productivity 
under tightly controlled pH and dissolved O2 (dO2) conditions.  
 
5.1 Transient bioproduction in chemically defined medium 
The increasing regulatory requirements for the manufacture of biopharmaceuticals demands 
a greater definition in the processes involved. This often results in strict guidelines in 
manufacturing with an increasing preference for parameters that can introduce significant 
variability. The evolution in growth medium is one example that has been well documented 
in the last 20 years, shifting over time from serum-containing, to protein-free and now, 
complete chemically defined medium. Chemically defined medium limits batch-to-batch 
variability, reducing the risk of contaminants derived from serum product, reducing costs and 
improving flexibility during bioprocess optimization. In the current work, we elected CD-CHO 
medium (Life Technologies) which has demonstrated to support high cell density and has 
subsequently been widely accepted by industry. Both the CHO-XL99 and XBP1 cell line 
were adapted into the CD-CHO medium through a step-wise adaption process where the 
cells were passaged into increasing proportions of CD-CHO until cells returned to normal 
doubling rates. Briefly, once the cells are fully adapted to CD-CHO, a transient bioproduction 
with an established feeding regime was used to compare the expression of two different 
mAbs. It is important to expand the study to other recombinant proteins to investigate the 
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transferability of results. Therefore, we have included Ab2 – a human IgG1 mAb (a different 
IgG sub-class to 3C12) in this study. The transient bioproduction was performed in CD-CHO, 
which is optimized to sustain high cell density. The feed used to supplement the 
bioproduction was CD EfficientFeed™ A and B, which has been specifically designed to 
improve cell growth kinetics and boost productivity of CHO cells. Using the established 
protocols examined in Chapter 3, the PEI mediated transfection was still performed at 2µg 
plasmid DNA mL-1 of culture (both 3C12 and Ab2 use single plasmid encoding both antibody 
chains). Furthermore, we’ve increased the starting transfection density to 3x106 cells mL-1 
to capitalize on the high cell growth potential offered by the enriched growth environment. 
The cultures were fed with CD EfficientFeed™ on Day 4 post-transfection at 15% of total 
culture volume as per manufacturer’s recommendation. Samples were taken on Days 2, 4, 
7 and 11 post-transfection for cell counting and viability, culture supernatants were also 
collected for ELISA to determine productivity. The qp was determined using the conventional 
method of calculation which is based on the change in mAb accumulation over the integral 
of viable cells. Detailed transfection protocol is described in Section 2.12.  
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Figure 18. Transient bioproduction in industrial relevant process. 
CHO-XL99 and XBP1 cell line adapted to CD-CHO were assessed for their performance in PEI mediated 
transient bioproduction of two different IgG antibodies. Each cell line is also tested for their response to 
commercially available feeds supplemented on Day 4 post-transfection. Cell density and viability is determined 
using Cedex Hires automated cell counter and mAb concentration is determined using ELISA. Experiment was 
performed in biological triplicates. A. Ab2 production Cell growth curve. B. Ab2 mAb accumulation. C. 3C12 
production cell growth curve. D. 3C12 mAb accumulation. E. Averaged qp calculated for the period from Day 
2 to Day 11 post-transfection.  
The results demonstrated that the XBP1 cell line significantly outperformed CHO-XL99 in 
transient bioproduction for the expression of both mAbs (Ab2 and 3C12). The CHO-XL99 
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was still superior in terms of growth as compared to the XBP1 cell line under both feeding 
and standard (non-feeding) conditions. However, under feeding conditions, the differences 
in peak cell density between CHO-XL99 and XBP1 were significantly reduced. Under 
standard conditions, the XBP1 cell line exhibited minimal growth, indicating a systemic 
problem post-transfection. However, the Day 11 cell density did show considerable 
improvement with the addition of Efficient FeedTM Kit, 2.2 fold increases for Ab2 samples 
and 1.5 fold increases for 3C12 samples. Although CHO-XL99 cell growth also showed 
improvements with Efficient FeedTM, the improvements were not as apparent as the XBP1 
cell line. Despite the modest increase in growth of the XBP1 cell line, the volumetric 
productivity was still substantially higher than CHO-XL99 in all conditions tested. For 
example, on Day 11, the XBP1 line expressing Ab2 reached 72 mg L-1, this equates to a 4 
fold increase in volumetric productivity, and a 4.4 fold increase when expressing 3C12. 
Interestingly, the feeding strategy was observed to have a greater impact on the XBP1 cell 
line compared to CHO-XL99 when examining final yields. Therefore, when we examined the 
qp for all conditions, we observed even a greater difference between XBP1 and CHO-XL99 
cell line. The increase in qp between the two cell lines ranged from 4.8 to 7.5 fold. Therefore, 
by defining the growth environment, it was easier to improve cell growth and the robustness 
of the cell lines in an industry relevant setting. Our translation and secretion engineering is 
valid: it is an inherent characteristic and not influenced be external changes. From these 
collective results, we have successfully targeted the improvement of the translation and 
secretion bottlenecks with the XBP1 cell line. 
 
5.2 Comparison of XBP1 and CHO-XL99 resistant pool quality 
Our transient bioproduction using the XBP1 cell line demonstrated encouraging results, 
increasing the qp 7.5 fold compared to the parental CHO-XL99 cell line. To further assess 
the advantage of augmenting the translation and secretion capacity in CHO cells, we 
examined its productivity in stable expression system and also the population distribution of 
high producers in the resistant pool to increase the probability of isolating high mAb 
expressing cells. Briefly, both XBP1 and CHO-XL99 cell lines were transfect with 3C12 mAb 
in a two vector system with the G418 selection marker via PEI mediated gene delivery. Two 
days post-transfection, G418 was added to a final concentration of 400µg mL-1. The cells 
were kept under selection pressure for 21 days, with the cell density maintained at 
approximately 1x106 cells mL-1 through routine cell passaging. The detailed method for 
resistant pool generation is described in Section 2.9. Once the resistant pool has been 
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generated, i.e. when the cells recover to >95% in viability and doubling time of approximately 
24 hrs, cells were examined for productivity and producer cell population distribution.  
5.2.1 XBP1 and CHO-XL99 resistant pool batch production 
Batch studies were performed to examine the productivity of our resistant pool generated 
from XBP1 and CHO-XL99 host cell lines using 125mL shaker flasks. The cells were seeded 
at 0.5x106 cells mL-1 in CD-CHO with no further supplementation. The cells were cultured 
for 7 days with cell counts performed periodically and supernatant collected for further 
productivity assessment. The results are depicted in Figure 19.  
 
Figure 19. Comparative batch productivity study in 125mL shaker flasks. 
The XBP1 and CHO-XL99 resistant pool producing 3C12 were cultured in 125mL vented shaker flask in 
humidified shaking incubator to investigate its performance in batch production. Samples were taken to 
determine its A. cell density and B. productivity via ELISA. The experiment was performed in duplicates. C. 
Vi
ab
le
  C
el
l  
D
en
si
ty
 (x
10
6  c
el
ls
 m
L-
1)
Viability %
mAb Accumulation in 125mL Shaker Flask
Days
m
A
b 
[c
on
c.
] m
g 
L-
1
0 2 4 6 8
0
5
10
15
XBP1
CHO-XL99
n = 2
Cell Specific Productivity of
resistant pools in batch production
CH
O-
XL
99
XB
P1
0.0
0.2
0.4
0.6
0.8
73 
 
The qp of both resistant pools during the batch production. D. Photo depicting the aggregated cell mass forming 
a ring inside the shaker flask. This was observed in both CHO-XL99 and CHO-XBP1. 
 
The batch productivity study demonstrated fundamental differences between the resistant 
pools generated from both the XBP1 and CHO-XL99 host lines. From the results, XBP1 and 
CHO-XL99 resistant pools demonstrated similar growth, reaching peak cell density over 
5x106 cells mL-1.The aggregate cell mass started to appear on Day 4 into the study with 
rapid accumulation in the following days. The cell mass accumulation was similar for both 
pools and therefore should have had little to no bearings on the productivity data. The mean 
volumetric productivity of XBP1 resistant pool was 11.03 mg L-1 on Day 7, while CHO-XL99 
resistant pool produced 3.95 mg L-1. This was almost a 3 fold increase in volumetric 
productivity. The difference in volumetric productivity was also reflected on the qp, where 
XBP1 resistant pool produced 0.68 pcd compared to 0.19 pcd from CHO-XL99. We 
observed that the XBP1 cell line had 3 fold increases in the volumetric productivity with a 
similar fold increase in specific productivity. This was very encouraging so we then 
proceeded to examine the population distribution of our resistant pools. 
 
Note: We observed an accumulation of cell mass, forming a ring on the inside surface of the 
flasks in the batch study as we did not add anti-clumping agents, this may have impacted 
on the true cell growth estimations (Figure 19D). However, as all cultures (CHO-XL99 and 
XBP1) demonstrated the same observation, we concluded that the cell count data is still 
comparative.  
5.2.2 Population distribution of XBP1 and CHO-XL99 resistant pools 
From our batch production, we were able to demonstrate the superior performance of the 
XBP1 resistant pool, we then employed the cell surface staining of secreting IgG to explore 
the population distribution of our resistant pools. Cells were sampled from both resistant 
pools 48 hrs post passaging and stained with detection antibody conjugated to APC. The 
samples were then subjected to flow cytometer and the results depicted in Figure 20. 
   
74 
 
 
Figure 20. mAb producer population distribution of CHO-XL99 and XBP1 derived resistant pool. 
The 3C12 producing resistant pool generated from XBP1 and CHO-XL99 cell line was assayed for their mAb 
producing cell population distribution using cell surface staining of secreting IgG with detection antibody 
conjugated to APC and followed by flow cytometry analysis. 20,000 viable single cells were analyzed and a 
discretionary gate was assigned at 103 RFU to indicate good producers. A. XBP1 cell line was examined for 
its GFP fluorescence to ensure the continued expression of XBP1-S, which is incorporated upstream of IRES-
GFP. B. The mAb producing population distribution within the resistant pool generated from XBP1 host cell 
line. 25.1% of the population was considered good producers. The mean fluorescent intensity was 2814 while 
median fluorescent intensity was 340. C. The mAb producing distribution within the resistant pool generated 
from CHO-XL99 host cell line. 17.1% of the population was considered good producers. The mean fluorescent 
intensity was 1660 and median fluorescent intensity was 322. 
 
Following the introduction of the mAb 3C12 into the XBP1 cell line, we ensured that XBP1-
S was still expressed. As XBP1-S is incorporated into an IRES-GFP system, the identical 
GFP fluorescent profile indicated that XBP1-S was still maintained at high levels. We 
analyzed the population distribution for mAb producing cells by nominating a gate at 103 
RFU to indicate good producers. 25.1% of the cells from XBP1 resistant pool were 
considered to be good producers, while only 17.1% of cells from the CHO-XL99 resistant 
pool were included in this gate. This represents a 1.5 fold increase or 50% increase in the 
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possibility to isolate a good producing clone. However, from the population distribution we 
also noticed that the majority of the cells from both resistant pools were non-producers. The 
stable integration of plasmids into the genome is largely relying on the cellular DNA damage 
and repair mechanism, thus the integration of large pieces of DNA is a low probability event, 
and this is compounded by Heavy and Light chain of our antibody in two separate vectors 
(6Kb and 5.2Kb). Moreover, our selection marker only constitutes around 10-15% of the total 
fragment size, therefore there is no guarantee that G418 resistant equates to the presence 
of our mAb genes. The stable integration through DNA damage and repair mechanism is a 
random event, therefore, the cut in the plasmid may potentially separate the selection 
marker from the GOI, resulting in large number of false positives that we are seeing. This 
explains that despite the considerable increase in qp and volumetric productivity from our 
XBP1-S engineered host cell, the overall yield still left a lot to be desired. As the majority of 
cells comprising both resistant pools are resistant non-producers (false positives), they will 
have a significant detrimental effect on the overall product yield. The false positives 
represent a major inefficiency in the system.   
 
5.3 Comparison of XBP1 and CHO-XL99 resistant pool performance in 
stirred-tank Bioreactor 
Large-scale stirred-tank (STR) bioreactors are the vessel of choice for the manufacture of 
therapeutic proteins. The traditional STR bioreactor provides a controlled and regulated 
environment for cell growth as well as simplicity and ease of scale-up, therefore it is 
imperative that the resistant pool generated from the XBP1 host cell line can propagate in 
the STR bioreactor. The reduced gas-liquid interphase and the higher working-to-total 
volume ratio in STR bioreactors means that gas and nutrient exchange need to be achieved 
through different means than that of shaker flask on a shaking platform. Active gas sparging 
and mixing using an impeller ensures that nutrient availability and dO2 is homogeneous 
throughout the vessel. The changes in culturing conditions may raise unwanted effects in 
cell growth and productivity, therefore it is imperative that the engineered host cell line is 
assessed for its performance in an STR bioreactor. One of the most critical assessments for 
growth in an STR Bioreactor is the cells response to mechanical shear stress generated 
from mixing using impellers. As the impellers rotate to mix, it generates small fluid turbulence 
– called eddies. Eddies at the gas-liquid inter-phase, such as bubbles from the gas sparger, 
can cause the bubbles to break. The breakup of bubbles can thus cause shear stress and 
damage to nearby cells [114, 115]. In our bioreactor study, we wish to examine that the 
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changes in culturing conditions in an STR bioreactor does not affect the growth and 
productivity of our XBP1 resistant pool. We cultured both resistant pools generated from 
XBP1 and CHO-XL99 host cells at 800 mL working volume in a 1L Applikon Minibioreactor 
at stirring speed of 170 rpm with a marine impeller and controls for pH, dissolved oxygen 
(dO2) and temperature (our bioreactor setup is depicted in Figure 21). Our process will 
involve supplementing Efficient A and B at 15% of total volume on Day 4 as per our feeding 
regime for transient bioproduction. We will also supplement the culture medium with 0.4% 
(v/v) of Anti-clumping agent to prevent the aggregation of cell mass. We will take daily 
samples to monitor cell growth and viability. The bioreactor pH, dO2 and oxygen 
consumption profile is depicted in Figure 22.   
 
 
Figure 21. Applikon Minibioreactor setup to compare resistant pools’ performance in glass STR 
Bioreactor. 
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      A 
 
Figure 22. Plot of pH, dO2 (%) and total O2 consumption for resistant pools grown in STR 
Bioreactors. 
      B 
The resistant pools’ were cultured for 8 days. The set point for pH (black line) control is 7.0 and is controlled 
using CO2 and 0.5M sodium bicarbonate. The set-point for dO2 (red line) control is at 40% saturation in 
atmospheric air, it is controlled with the addition of 20 mL min-1 Clean Air plus pure O2 in mL min-1. Total O2 
(green line) is the volume of pure O2 gas pumped into the vessel through ring sparger. Elapse culture time in 
hours is displayed on the x-axis. Both cultures were fed with Efficient Feed A and B on Day 4 at 15% of total 
culture volume. A. XBP1 derived mAb producing resistant pool. B. CHO-XL99 derived mAb producing resistant 
pool. 
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Figure 23. Comparative fed-batch productivity study in STR Bioreactors. 
The XBP1 and CHO-XL99 resistant pool producing 3C12 were cultured in 800mL working volume in 1L 
Applikon Minibioreactor to investigate its performance in fed-batch production. Samples were taken to 
determine its A. cell density and B. productivity via ELISA. C. The qp of both resistant pools during the fed-
batch production in STR Bioreactor. 
 
Our STR Bioreactor study resulted in similar trends observed from the shaker flask batch 
production. The XBP1 derived mAb producing cell line exhibited a higher final volumetric 
productivity.  By using a scale-down bioreactor model, we are able to control the different 
factors that may have impact on the growth environment, i.e. dO2, pH, temperature and fluid 
dynamic forces generated through mixing. Operating the impeller at 170 rpm did not 
negatively impact the cell growth. The fed-batch production achieved higher cell densities 
than batch production, the CHO-XL99 derived resistant pool reached 12.5x106 cell mL-1 
peak cell density, while the XBP1 derived resistant pool reached 9.7 x106 cell mL-1 peak cell 
density. The oxygen consumption rate also concurred with the growth data, where we 
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observed steady increase in oxygen consumption concurrent with the increase in cell density 
and the sharp drop in oxygen consumption as the cells enters death phase. While there are 
a number of factors that could impact the cell viability, from the profile, the timing and change 
in growth suggests that there could be a nutrient limitation. We speculate that both cultures 
were limited by available energy sources due to the inability to efficiently utilize lactate to 
feed into the TCA cycle, resulting in the rapid decline in cell viability. Although we were not 
able to measure the presence of glucose and lactate, we can infer their availability through 
pH control. During the initial phase of the production, we observed that the pH decreases 
steadily possibly from the accumulation of lactate as the by product from glycolysis. However 
as glucose availability became limiting, the cells would be required to switch to efficient 
oxidation of lactate to feed into the TCA cycle for energy production. If the cells did switch 
to lactate oxidation, one should observe the steady rise in pH, which was not the case for 
either of our resistant pools. Therefore, we conclude that the depletion of energy source was 
one of the main causes for the rapid decrease in cell viability. There has been significant 
interest in reducing lactate levels whether it is through the over-expression of lactate 
dehydrogenase or feeding regimes to improve lactate consumption, while these changes 
were not assessed here, it is clear that the absence of a prolonged stationary phase has 
significant impact on productivity. Even with this observation, both cell lines demonstrated a 
similar mAb accumulation trend to the shaker flask batch production. The CHO-XL99 
resistant pool reached 4.8 mg L-1 in final mAb titer, whereas the XBP1 resistant pool reached 
15.3 mg L-1, which equates to approximately a 3 fold increase in volumetric productivity. This 
difference in volumetric productivity was also observed in the average qp; 0.15 pcd for the 
CHO-XL99 resistant pool and 0.63 pcd for the XBP1 resistant pool.   
 
Industrial scale bioproduction, where the working volume can often exceed thousands of 
liters, has very different considerations compared to that of lab scale systems. One of the 
biggest challenges in large scale production is mixing; sufficient mixing for mass transfer, 
gas exchange, heat transfer and nutrient/waste transfer all need to be considered. Mixing is 
typically achieved with stirring impellers with a gas sparger below. However, due to the 
absence of a cell wall, mammalian cells can be susceptible to mechanical stress caused by 
mixing from stirring impellers. Therefore, as part of the cell line development, it is critical to 
assess the performance of production cell lines in small scale STR bioreactors. Our 
comparative fed-batch production in a 1L STR bioreactor aimed to assess the scalability of 
XBP1 and CHO-XL99 derived mAb resistant pool as well as the impact of the mechanical 
stress on cells. The results from the STR bioreactor fed-batch study demonstrated a similar 
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trend compared to the shaker flask study, indicating the robustness and good scalability of 
the XBP1 host cell line. The feeding regime significantly improved the peak cell density over 
shaker flask batch production for both resistant pools. With the increase in cell density, the 
volumetric productivity also increased accordingly, indicating that the bioreactor 
environment did not adversely impact on cell growth and productivity. The superior 
performance of the XBP1 resistant pool remained evident in STR Bioreactor fed-batch 
production, the XBP1 resistant pool exhibited a 3 fold increase in volumetric productivity and 
a 3.5 fold increase in qp.  
 
5.4 Conclusion 
In this chapter, we investigated the performance of our XBP1 host cell in industrially relevant 
conditions. We adapted both CHO-XL99 and XBP1 cell lines into CD-CHO medium which 
is optimized to support high cell density as opposed to the more outdated CHO-SFMII 
employed in our earlier proof-of-concept studies. Our strategy for using CHO-SFMII in earlier 
work was to reveal inadequacies in the cell line, especially as we were concerned with the 
potential impact on gene expression analysis with the presence of growth factors in 
optimized medium such as CD-CHO. Once both cell lines were adapted into CD-CHO, we 
successfully validated earlier observations in industrially relevant conditions. We tested the 
Transient bioproduction for two different mAbs to demonstrate the potential of the XBP1 cell 
line as a platform cell line. In both instances, the XBP1 cell line significantly outperformed 
CHO-XL99 both in volumetric productivity in qp. Further, the feeding strategy had a much 
more pronounced effect in our XBP1 cell line. As we do not have information on Efficient 
Feed composition, it is difficult to speculate the reason behind the positive response from 
XBP1 cell line.  
 
A high expressing and robust population can eliminate the need for laborious screening in 
stable cell line development. Therefore, we examined the heterogeneity and expression 
levels of both resistant pools. While the volumetric productivity was several folds higher in 
XBP1 derived resistant pool, the population distribution data suggests that there is only a 
moderate increase in the percentage of high expressing clones in the population. Evidently, 
this result is also masked by the large percentage of non-expressers in the resistant 
population. This is often due to the stringency of the selection method and the process of 
transfection, random integration and subsequent epigenetic changes. The enhancement of 
translation and secretion capacity of the XBP1 cell line does not mitigate limitations at the 
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transcription level. Future work will investigate the combinatorial approach of targeting 
transcription, translation and secretion engineering. In fact, there are several technologies 
such as UCOE, S/MARs as well as process innovations such as the ClonePix FL that can 
be combined with the XBP1 cell line to improve the overall process cell line development. 
Finally, we tested the scalability of our XBP1 host cell, specifically assessing its 
bioproduction potential in a stirred-tank bioreactor. The scale down model of both CHO-
XL99 and XBP1 derived resistant pools were evaluated in a 1L STR Bioreactor with pH and 
dO2 controls and feeding regime. Both resistant pools achieved higher cell density compared 
to previous batch production in shaker flasks. The superior performance of the XBP1 cell 
line remained evident, exhibiting near identical productivity outperformance as observed in 
batch production. This demonstrates that the XBP1 cell line is a suitable production host in 
a Bioreactor environment. The mechanical stress which is commonly associated with STR 
did not seem to have a negative impact on either XBP1 cell growth or productivity. Further, 
STR is very scalable up to large volume commercial production [94, 116], therefore the 
XBP1 engineered cell line demonstrated its suitability for use in commercial production.   
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6.  Conclusion and Discussions 
Mammalian expression systems, particularly expression in CHO cells, are the most widely 
adopted production host for the manufacturing of therapeutic proteins such as mAbs. They 
are the production host of choice due to their ability to perform the necessary and human-
like post-translational modifications such as glycosylation. The method of production is often 
split into two categories, stable and transient systems. While there is a constant change in 
the landscape of biologics manufacturing, both systems have a place in industry and are 
used extensively in both early R&D and commercial manufacturing. The biggest challenge 
with the systems remains with the productivity which will impact both timelines and costs. 
For transient expression systems, the level of volumetric productivity is often too low for 
large scale manufacturing, while the generation of a suitable production clone in stable 
systems is often laborious, time and resource intensive. In order to create a suitable 
production cell line, it can take between 6-8 months, with the productivity of the final clone 
a major focus of the development process. The translation and secretion stage in the 
production of large, complex recombinant proteins has been identified as the rate-limiting 
step. Overloading of the translation and secretion machinery can trigger the UPR which 
results in cell apoptosis when not completely resolved. The UPR is regulated by three 
overlapping pathways; PERK, IRE1 and ATF6 pathways which together execute both pro-
apoptosis and pro-survival responses. The downstream target of IRE1 pathway – XBP1 is 
the major focus of this study. The XBP1 protein has two isoforms derived from alternate 
mRNA splicing by activated IRE1 during UPR. The constitutively expressed unspliced XBP1, 
the predominant splice form in unstressed cells have no transactivator functions. Whereas 
spliced XBP1, up-regulated during UPR, translates into a potent transcription activator which 
regulates a wide array of cytoprotective genes. The downstream targets of XBP1-S include 
folding proteins, quality control proteins and various secretory proteins. The activation of 
UPR will assist in the alleviation of intracellular bottlenecks, if successful, cells return to 
steady state resulting in deactivation of IRE1 and down-regulation of XBP1-S. XBP1-US, 
through its regulatory mechanism is known to complex with XBP1-S for degradation to 
proceed to revert the cells back to steady state. Therefore, XBP1 splice ratio is a powerful 
indicator of the up-regulation of ER and Golgi associated gene targets to enhance translation 
and secretion capacity.  
 
This thesis aims to create a host cell with enhanced translation and secretion capacity 
through the manipulation of the XBP1 splice ratio. By investigating the concept of the XBP1 
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ratio, we aim to create a new host cell line suitable for both transient and stable bioproduction. 
For both production systems, the introduction of the gene of interest (GOI) can cause 
considerable demand on the translation and secretion machinery leading to UPR induced 
apoptosis. Transient bioproduction often encounters the challenge to produce as much 
product as possible in the shortest timeframe, which will undoubtedly induce cellular stress 
at every stage of recombinant protein expression. The second application would be in stable 
bioproduction, the generation of stable and high expressing cell lines have traditionally been 
a random process of screen and select. As many continue to work towards unravelling this 
blackbox approach, there is a need to continuously improve current systems to complement 
this investigation. For cell line screening and selection from a resistant pool, the quality of 
the pool is the bottleneck in the process. This is evident during the screening process where 
often thousands of clones will be evaluated until a production clone with suitable attributes 
is identified. Therefore a high quality pool, i.e. a resistant pool with high percentage of high 
producers, will have strong impact on the time and resources required for the screening and 
selection. Here, we hypothesized that potential high producers may be lost in the resistant 
pool due to their inability to resolve translation and secretion stress arising from the influx of 
demand to synthesize the GOI. With new innovations in transfection, an efficient transfection 
may result in high copy number of the GOI which would also require the complementary 
downstream machinery to process the driven in expression. An inability to accommodate to 
this downstream would lead to UPR apoptosis. Therefore, by creating a host cell line with 
superior translation and secretion machinery, we can better encapsulate the population of 
efficiently transfected cells, resulting in a greater percentage of high producers in the 
resistant pool.  
 
6.1 XBP1 splice ratio to enhance host cell translation and secretion capacity 
As previously mentioned, translation and secretion have often been considered as the rate-
limiting step, therefore we attempted to understand the translation and secretion traits of 
different production cell lines. We screened nine mAb-producing clonal CHO-XL99 cell lines 
to investigate the correlation between the specific productivity and a panel of translation and 
secretion related gene targets using semi-quantitative PCR. Amongst the gene targets 
examined, several have been reported in the literature to improve the productivity of 
recombinant proteins, such as BiP, PDI, YKT6, ATF4 and XBP1-S. Our correlation analysis 
examined the Pearson’s correlation coefficient of qp to each gene target. The results 
suggested that there was low to moderate correlation between qp and translation and 
84 
 
secretion targets. These results were a reflection of the observations in the literature where 
the over-expression of these targets yielded mixed results. Amongst all the gene targets 
tested, XBP1-S demonstrated the highest correlation coefficient of 0.59 and XBP1-US 
exhibited a moderate negative correlation of -0.52.  When we examined the correlation of 
XBP1 splice ratio with qp, we observed a strong positive correlation coefficient of 0.84. 
Furthermore, if we assume that the relationship between XBP1 splice ratio and qp is non-
linear, thus applying Spearman’s ranked method to describe the relationship, then the 
correlation coefficient is 0.97. The benefits of XBP1-S during UPR have been well 
documented and also its critical role in the expansion of translation and secretory machinery 
during antibody production of differentiating plasma cells. Nevertheless, XBP1-S over-
expression to improve bioproduction has not always given the desired outcome. From the 
differential profiling, we suggest that this is due to the abundance of the endogenous 
expression of XBP1-US which is mitigating the positive effect of XBP1-S. As XBP1-US is a 
negative regulator of XBP1-S, any attempts to over-express XBP1-S need to be at a 
sufficient abundance to overcome the intracellular levels of XBP1-US. We further tested the 
potential of XBP1 splice ratio as a target to improve recombinant protein productivity using 
our novel XBP1 reporter system for the detection of XBP1 splicing in real-time. This reporter 
system takes advantage of the frameshift during IRE1 splicing of XBP1 mRNA to produce 
functional GFP only after the splicing event. We used the reporter line to correlate the effect 
of XBP1 splicing during mAb bioproduction. The results revealed a strong positive 
correlation between the XBP1 splicing and qp. In fact, by tracking the cells during the 
transient bioproduction it revealed that peak mAb expression is superseded by XBP1 
splicing (thus an influx of available XBP1-S) as a way to overcome the impending stress. 
This study is the first in its nature to successfully depict the effect of XBP1 splicing on mAb 
expression. Together, the results demonstrated strong justification of XBP1-1 splice ratio as 
a target for cell engineering. 
 
6.2 XBP1 as host cell line for bioproduction 
To create a host cell line for bioproduction, we used an XBP1-S bicistronic vector 
incorporating an IRES followed by GFP enriched high XBP1-S expressing population. 
Following enrichment using FACS, the enriched population, or XBP1 cell line was 
characterized by qPCR to establish the high XBP1 splice ratio, along with other translation 
and secretion gene targets. The two important UPR apoptotic markers, ATF4 and CHOP 
were both at baseline levels, thus this presents a unique case in host cell line engineering 
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where through targeting XBP1 ratio, and we are able to enrich a population of cells that 
presented favorable traits for bioproduction. Through this process of over-expressing XBP-
1S and enrichment for high splice ratio cells, it was possible to specifically up-regulate the 
cytoprotective machinery of the cells without increasing the effects of the UPR associated 
apoptotic pathway. Contrary to current literature approaches of host cell engineering where 
only one or a small subset of ER/Golgi associated genes are over-expressed [117-122], 
here we enhanced the entire translation and secretion cellular function. Due to the inherent 
complexity in cellular translation and secretion, we believed in the over-expression of 
transcription factors such as XBP1-S for the up-regulation of cellular function. The resulting 
XBP1 cell line demonstrated increase in expression of all the translation and secretion 
markers tested which included folding, secretion and quality control proteins. Thus we have 
created a cell line with enhanced translation and secretion functions. 
6.2.1 Transient Bioproduction 
We tested the potential of our XBP1 line with enhanced translation and secretion capabilities 
in transient bioproduction of mAb. Transient expression has gained popularity in industry 
due to its simplicity, however the method is often hampered by the productivity of the cells. 
Several cell lines are commonly used such as HEK293, CAP-T and CHO. Much focus has 
been on CHO as it is the preferred host in stable systems. The proof of concept study had 
been performed in simple protein-free growth medium; CHO-SFMII. The application of 
bioprocess techniques to assess different growth conditions and feeds would often improve 
stagnation in growth. Therefore, we first opted for a more basic medium to assess all aspects 
of the cell line. The direct comparison of XBP1 to a standard CHOK1 derived CHO-XL99 
line in transient bioproduction demonstrated almost double in the qp of our XBP1 cell line. 
As our focus is solely on relieving the translation and secretion bottleneck, therefore the qp 
is the most relevant indicator of cellular translation and secretion capability. The result 
confirmed the benefits of an expanded translation and secretion capacity on recombinant 
protein production. We then performed transient bioproduction in the industrially relevant 
medium – CD-CHO with feeding strategy. The transient bioproduction in CD-CHO medium 
combined with a feeding strategy further emphasized the superior capabilities of XBP1 cell 
line. We tested the transient bioproduction with two different mAbs, and in both experiments 
the XBP1 cell line significantly outperformed CHO-XL99. The qp increased by approximately 
7 fold in the XBP1 cell line. Interestingly, the feeding strategy used also elicited a greater 
response from the XBP1 cell line. While it is difficult to establish the reasons behind this 
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difference without medium formulations, the presence of certain feed component seemed to 
have a synergetic effect with an expanded translation and secretion capacity. 
6.2.2 Stable Bioproduction in Stirred-tank bioreactor 
Stirred-tank bioreactor (STR) is integral for large scale industrial production, it remains the 
standard for industry, and often small scale shake flask growth does not equate to growth in 
a bioreactor. Therefore, a scale down bioreactor model would provide invaluable information 
on the growth kinetics with new bioreactor conditions. We assessed the performance of our 
XBP1 and CHO-XL99 derived mAb producing stable pools in a stirred-tank bioreactor with 
feeding strategy. The controlled conditions of the bioreactor provided an environment which 
showed similar growth and productivity trends to the shake flask studies. In fact, rather than 
any adverse effects due to the mechanical stresses from the bioreactor, there was a further 
reduction in growth disparity observed between the cell lines. Therefore, the results show 
that XBP1 cell line would have the pre-requisites for scalability and “fit-for-purpose” when 
used in large scale manufacturing. The positive results achieved in our STR will serve the 
basis of future bioprocess studies using the XBP1 cell line. Bioprocess optimizations have 
great potential to improve the volumetric productivity and also to maintain high product 
quality which was not investigated in the current thesis. One possible future application for 
the XBP1 cell line is in high cell density bioprocess such as perfusion bioreactor. In perfusion 
bioreactor design, cell mass can be retained using various methods such as gravity-based 
cell settlers, spin-filters, centrifuge, cross-flow or alternating tangential flow filters and even 
acoustic cell settlers [123]. The benefits of high qp will be even more pronounced combining 
synergetic benefits with high cell density leading to much smaller working volume required 
for the necessary productivity output, this will have significant capital expenditure and logistic 
savings.  
 
6.3 Post-transfection Differential Gene Expression Profiling 
Our results in the post-transfection differential gene expression profiling revealed several 
interesting findings. Firstly, despite further increase in XBP1 splice ratio (triggered by the 
splicing of endogenous XBP1-US), our translation and secretion markers remained relatively 
unchanged in our XBP1 cell line compared to and obvious increase in CHO-XL99 post-
transfection. This led us to believe that the up-regulation of the translation and secretion 
machinery (i.e. expression of folding, secretion and quality control proteins etc.) have been 
saturated by XBP1-S. As the genome copies of these ER/Golgi proteins remained 
unchanged, if their promoter region had already been occupied with XBP1-S, further 
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increase in available XBP1-S can no longer increase the expression of said proteins. 
Another interesting observation was that even with the preconditioning of the expanded 
translation and secretion capacity, the XBP1 cell line demonstrated higher expression of 
UPR apoptotic marker ATF4 and CHOP.  This was quite a surprise as we expected that the 
XBP1 cell line would be better equipped to resist ER stress. The increase in expression of 
UPR associated apoptotic marker also coincided with the slowdown in growth rate. Despite 
our efforts to use optimized medium and feeding strategies to overcome the slowdown in 
growth post-transfection, it remained to lag behind CHO-XL99. The new optimized culture 
medium and feeding strategy significantly increased the cell density and culture longevity, 
however post-transfection CHO-XL99 demonstrated more than a two-fold increase in peak 
cell density over the XBP1 cell line. Therefore, we speculate that there may be a 
fundamental difference in cell proliferation which stems from the continued presence of 
XBP1-S which cannot be mitigated from the addition of growth factors. XBP1-S is the critical 
transcription factor for the differentiation of B-cells to plasma cells. One of the hallmarks of 
an antibody secreting plasma cell is that it enters into quiescence to stop proliferation [74, 
124], thus it is not unfathomable that XBP1-S may have targets which limits cell proliferation 
to focus cellular resources on translation and secretion. Therefore, to address the XBP1 cell 
line’s reduced cell growth post-transfection, it is important to understand global changes 
arisen from the over-expression of XBP1-S, specifically focusing on cell cycle and 
proliferation related gene expressions. Recent advances in Next generation sequencing 
technologies can provide the tools necessary in understanding the global changes induced 
from the over-expression of XBP1-S. 
 
6.4 Population distribution of high producers and the construction of 
resistant pool using XBP1 as host cell. 
Our investigation on the population distribution of high mAb producers post-transfection 
supported the notion that the XBP1 cell line was a better host for transient bioproduction 
due to the higher proportions of cells identified as high mAb producers. This observation 
was further explored in the construction of stable resistant pools in the cell line development 
process as the starting point for the isolation of production clone. The probability of isolating 
high producers is a critical quality attribute of the resistant pool. We believed that the higher 
number of high producers within the transfected population would also increase the 
probability of isolating suitable production clones in resistant pool. To our knowledge, there 
have been no similar studies to investigate the probability of isolating high producers. The 
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results demonstrated a substantial increase in the volumetric productivity in the resistant 
pool but only a moderate increase in the percentage of high mAb producers. The increase 
in percentage of high mAb producers in our stable resistant pool was considerably lower 
than what was observed in our transient studies. Upon further examination, it was revealed 
that there were overwhelmingly large proportions of resistant, non-producers (false 
positives), which severely impacted on our assessment of the number of high producers. 
We believe that the high number of false positives derived from the ineffective integration 
and selection of our GOI. The stable integration of our GOI into the host genome relies on 
the DNA repair mechanism through either homologous or non-homologous (random) 
integration. This particular step can be very inefficient as several factors can impact on the 
desired outcome of high transcription of our GOI. The transfected plasmid DNA harboring 
the GOI needs to be integrated into an active section of the genome that is often accessible 
or “hot spot”. As the selection marker (antibiotic resistant gene) is not tethered to the GOI, 
scenarios where only the antibiotic resistant gene is stably integrated while the GOI is either 
removed or silenced are likely, as evident from our high percentage of antibiotic resistant 
and non-producing cells. While we have enhanced the translation and secretion machinery 
of our XBP1 cells, in the case of our resistant pool, the rate-limiting step may be the copies 
of available GOI mRNA. It is important to note that, an ideal production cell would have 
overcame all obstacles associated with high productivity while maintaining high growth rate, 
whether the obstacle was derived from transcription, translation and secretion or metabolic 
limitations. The aim of this thesis is to pre-eliminate solely the limitations encountered during 
recombinant protein translation and secretion, therefore the benefits of the XBP1 cell line 
will vary depending on the expression settings.  Future work will investigate the 
combinatorial approach of host cell engineering to pre-eliminate further challenges the cell 
may encounter. Saunders et al. [113] produced a useful review of available chromatin 
function modifying elements which may be suitable to apply in conjunction with XBP1 for 
host cell engineering. 
 
6.5 Final conclusion and future directions 
This thesis identified XBP1 splice ratio as a host cell engineering target to produce a 
translation and secretion enhanced cell line for therapeutic protein bioproduction. We 
validated the findings through the creation of the XBP1 host cell line which exhibited higher 
expression of folding, secretion and quality control proteins. The XBP1 host cell line showed 
distinct improvements in volumetric productivity compared to the control cell line in transient 
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bioproduction. The increase in final product titer stems from the considerable increase in 
cell specific productivity conferred by the enhanced translation and secretion capacity. 
However, despite the significant productivity improvements achieved from the expansion of 
cellular translation and secretion capacity using XBP1 splice ratio manipulation, there are 
considerable future scope for further improvements. Product titer can be affected by a wide 
range of factors associated with both cellular and culturing conditions, therefore a 
combinatorial approach with possible synergetic outcomes will be the most effective method 
to boost product titer. In this thesis, we have demonstrated that translation and secretion 
engineering can lead to multi-fold increases in cell specific productivity, therefore our 
recommendations for future work is to focus on increasing the number of producer cells. The 
resistant pool population distribution depicted in Section 5.2.2 provided a telling indication 
of the ineffectiveness of stable integration of the GOI. The compelling over-growth of false 
positive cells (resistant, non-producing cells) presents an obvious area for future 
improvements. Recent advances in homologous recombination for the insertion of GOI 
using CRISPR/Cas system [125, 126] may provide a more efficient method for the stable 
integration with significantly less false positives. Furthermore, genetic element additions 
such as UCOE and S/MARs [113] to ensure the accessibility of the GOI and to insulate it 
against gene silencing may also be highly beneficial. Cell engineering approaches to 
improve the metabolic efficiency, increasing cell proliferation and culture longevity should 
also be considered [127-129]. We also recommend in-depth investigations to elucidate the 
cause of cell growth impediment observed in our XBP1 engineered cell line. XBP1-S is 
critically involved in plasma cell differentiation [18, 74, 81, 82], and has been linked to cell 
quiescence post-plasma cell differentiation [74, 124]. Therefore it would be highly useful to 
understand the mechanistic details of slower cell growth due to over-abundance of XBP1-S. 
This can be achieve through comparative multi-omics approach to examine CHO-XL99 and 
CHO-XBP1 cell lines. As CHO cells are by far the most widely accepted and adopted 
production cell line, efforts to improve its bioproduction efficiency is well justified. We hope 
that future host cell engineering using combinatorial and rational design we can continue to 
de-bottleneck challenges associated with high titer recombinant protein expression in CHO 
cells.   
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8. Appendices 
A1. Vector Map of CHO XBP1 Splicing Reporter Plasmid 
 
A1.1. Modified XBP1-US sequence for XBP1 splicing reporter 
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A2. Vector Map of pNBF-XBP1S 
 
 
A3. XBP1-S Sequence Comparison from CHO-XL99 and NCBI Sequence 
A3.1 cDNA Sequence comparison 
CHOXL99         ATGGTGGTGGTGGCAGCGGCGCCGAGCGCGGCCACGGCGGCCCCGAAAGTACTGCTTCTA 60 
NCBI            ATGGTGGTGGTGGCAGCGTCGCCGAGCGCGGCCACGGCGGCCCCGAAAGTACTGCTTCTA 60 
                ****************** ***************************************** 
 
CHOXL99         TCGGGCCAGCCCGCCGCGGACGGCCGGGCGCTGCCACTCATGGTTCCAGGCTCGCGGGCA 120 
NCBI            TCGGGCCAGCCCGCCGCGGACGGCCGGGCGCTGCCACTCATGGTTCCAGGCTCGCGGGCA 120 
                ************************************************************ 
 
CHOXL99         GCAGGGTCCGAGGCGAACGGGGCGCCACAGGCTCGCAAGCGGCAGCGCCTCACGCACCTG 180 
NCBI            GCAGGGTCCGAGGCGAACGGGGCGCCACAGGCTCGCAAGCGGCAGCGCCTCACGCACCTG 180 
                ************************************************************ 
 
CHOXL99         AGCCCGGAGGAGAAGGCGCTGCGGAGGAAACTGAAAAACAGAGTAGCAGCGCAGACTGCC 240 
NCBI            AGCCCGGAGGAGAAGGCGCTGCGGAGGAAACTGAAAAACAGAGTAGCAGCGCAGACTGCC 240 
                ************************************************************ 
 
CHOXL99         CGAGATCGAAAGAAAGCCCGGATGAGCGAGCTGGAACAGCAAGTGGTGGATTTGGAAGAA 300 
NCBI            CGAGATCGAAAGAAAGCCCGGATGAGCGAGCTGGAACAGCAAGTGGTGGATTTGGAAGAA 300 
                ************************************************************ 
 
CHOXL99         GAGAACCAAAAACTTCTGTTAGAAAATCAGCTTTTGAGAGAGAAAACTCATGGCCTTGTA 360 
NCBI            GAGAACCAAAAACTTCTGTTAGAAAATCAGCTTTTGAGAGAGAAAACTCATGGCCTTGTA 360 
                ************************************************************ 
 
CHOXL99         ATTGAGAACCAGGAGTTAAGAACTCGCTTGGGAATGGATGTGCTGACTACTGAAGAGGCT 420 
NCBI            ATTGAGAACCAGGAGTTAAGAACTCGCTTGGGAATGGATGTGCTGACTACTGAAGAGGCT 420 
                ************************************************************ 
 
CHOXL99         CCAGAGACGGAGTCCAAGGGAAATGGAGTAAGGCCGGTGGCCGGGTCTGCTGAGTCCGCA 480 
NCBI            CCAGAGACGGAGTCCAAGGGAAATGGAGTAAGGCCGGTGGCCGGGTCTGCTGAGTCCGCA 480 
                ************************************************************ 
 
CHOXL99         GCAGGTGCAGGCCCAGTTGTCACCTCCCCAGAACATCTTCCCATGGATTCTGACACTGTT 540 
NCBI            GCAGGTGCAGGCCCAGTTGTCACCTCCCCAGAACATCTTCCCATGGATTCTGACACTGTT 540 
                ************************************************************ 
 
CHOXL99         GACTCTTCAGACTCCGAGTCTGATATCCTTTTGGGCATTCTGGACAAGTTGGACCCTGTC 600 
NCBI            GACTCTTCAGACTCCGAGTCTGATATCCTTTTGGGCATTCTGGACAAGTTGGACCCTGTC 600 
                ************************************************************ 
 
CHOXL99         ATGTTTTTCAAATGTCCATCCCCAGAGTCTGCCAATCTGGAGGAACTCCCAGAGGTCTAC 660 
99 
 
NCBI            ATGTTTTTCAAATGTCCATCCCCAGAGTCTGCCAATCTGGAGGAACTCCCAGAGGTCTAC 660 
                ************************************************************ 
 
CHOXL99         CCAGGACCTAGTTCCTTACCAGCCTCCCTTTCTCTGTCAGTGGGGACCTCATCAGCCAAG 720 
NCBI            CCAGGACCTAGTTCCTTACCAGCCTCCCTTTCTCTGTCAGTGGGGACCTCATCAGCCAAG 720 
                ************************************************************ 
 
CHOXL99         CTGGAAGCCATTAATGAACTCATTCGCTTTGACCATGTATACACCAAGCCTCTAGTCTTA 780 
NCBI            CTGGAAGCCATTAATGAACTCATTCGCTTTGACCATGTATACACCAAGCCTCTAGTCTTA 780 
                ************************************************************ 
 
CHOXL99         GAGATCCCTTCTGAGACAGAGAGTCAAACTAATGTGGTAGTGAAAATTGAGGAAGCACCT 840 
NCBI            GAGATCCCTTCTGAGACAGAGAGTCAAACTAATGTGGTAGTGAAAATTGAGGAAGCACCT 840 
                ************************************************************ 
 
CHOXL99         CTCAGCTCTTCAGAGGAGGATCACCCTGAATTCATTGTCTCAGTGAAGAAAGAACCTTTG 900 
NCBI            CTCAGCTCTTCAGAGGAGGATCACCCTGAATTCATTGTCTCAGTGAAGAAAGAACCTTTG 900 
                ************************************************************ 
 
CHOXL99         GAAGAAGACTTCATTCCAGAGCCGGGCATCTCAAACCTGCTTTCATCCAGCCACTGTCTG 960 
NCBI            GAAGAAGACTTCATTCCAGAGCCGGGCATCTCAAACCTGCTTTCATCCAGCCACTGTCTG 960 
                ************************************************************ 
 
CHOXL99         AAACCATCTTCCTGCCTGCTGGATGCTTATAGTGACTGTGGATATGAGGGCTCCCCTTCT 
1020 
NCBI            AAACCATCTTCCTGCCTGCTGGATGCTTATAGTGACTGTGGATATGAGGGCTCCCCTTCT 
1020 
                ************************************************************ 
 
CHOXL99         CCCTTCAGTGACATGTCTTCTCCACTTGGTATAGACCATTCTTGGGAGGACACTTTTGCC 
1080 
NCBI            CCCTTCAGTGACATGTCTTCTCCACTTGGTATAGACCATTCTTGGGAGGACACTTTTGCC 
1080 
                ************************************************************ 
 
CHOXL99         AATGAACTCTTTCCCCAGCTAATTAGTGTCTAA 1113 
NCBI            AATGAACTCTTTCCCCAGCTGATTAGTGTCTAA 1113 
   ********************.************ 
 
A3.2 Translated Protein sequence comparison 
CHOXL99         MVVVAAAPSAATAAPKVLLLSGQPAADGRALPLMVPGSRAAGSEANGAPQARKRQRLTHL 60 
NCBI            MVVVAASPSAATAAPKVLLLSGQPAADGRALPLMVPGSRAAGSEANGAPQARKRQRLTHL 60 
                ******:***************************************************** 
 
CHOXL99         SPEEKALRRKLKNRVAAQTARDRKKARMSELEQQVVDLEEENQKLLLENQLLREKTHGLV 120 
NCBI            SPEEKALRRKLKNRVAAQTARDRKKARMSELEQQVVDLEEENQKLLLENQLLREKTHGLV 120 
                ************************************************************ 
 
CHOXL99         IENQELRTRLGMDVLTTEEAPETESKGNGVRPVAGSAESAAGAGPVVTSPEHLPMDSDTV 180 
NCBI            IENQELRTRLGMDVLTTEEAPETESKGNGVRPVAGSAESAAGAGPVVTSPEHLPMDSDTV 180 
                ************************************************************ 
 
CHOXL99         DSSDSESDILLGILDKLDPVMFFKCPSPESANLEELPEVYPGPSSLPASLSLSVGTSSAK 240 
NCBI            DSSDSESDILLGILDKLDPVMFFKCPSPESANLEELPEVYPGPSSLPASLSLSVGTSSAK 240 
                ************************************************************ 
 
CHOXL99         LEAINELIRFDHVYTKPLVLEIPSETESQTNVVVKIEEAPLSSSEEDHPEFIVSVKKEPL 300 
NCBI            LEAINELIRFDHVYTKPLVLEIPSETESQTNVVVKIEEAPLSSSEEDHPEFIVSVKKEPL 300 
                ************************************************************ 
 
CHOXL99         EEDFIPEPGISNLLSSSHCLKPSSCLLDAYSDCGYEGSPSPFSDMSSPLGIDHSWEDTFA 360 
NCBI            EEDFIPEPGISNLLSSSHCLKPSSCLLDAYSDCGYEGSPSPFSDMSSPLGIDHSWEDTFA 360 
100 
 
                ************************************************************ 
 
CHOXL99         NELFPQLISV 370 
NCBI            NELFPQLISV 370 
                ********** 
 
 
A4. Quantitative PCR Primer Sequences 
 
Primer Sequence Annealing Temp (C)
Product 
Size
XBP1-S Fwd derived from 
NM_001244049.1
CTGAGTCCGCAGCAGGTGCA 58 130bp
XBP1 Rev GACAGGGTCCAACTTGTCCAG 56
XBP1-US Fwd derived from 
NM_001244047.1
GACTACGTGCACCTCTGCAG 56 138bp
CHO BiP Fwd derived from 
NM001246739.2
GTGTACTGATCTGCTAGGGC 55
CHO BiP Rev derived from 
NM001246739.2
GCAGTAAACAGCCACTTGGGC 56
CHO Calnexin Fwd derived from 
EGW02891
GATGGAAAGTGGGAGGTAGATG 55
CHO Calnexin Rev derived from 
EGW02891
CTTGGTATCAAACAGGAAGGGC 55
PDI3 Fwd NM_001246774.1 AGGCTTGCCCCTGAGTATGAA 54
PDI3 Rev NM_001246774.1 CTGACAATTCCATCGGCAGTC 54
Sec23A Fwd XM_003502990.1 GAAGAACGAGATGGGGTCCG 55
Sec23A Rev XM_003502990.1 CAGGCTCGTACTGAATGGGTG 56
YKT6 Fwd XM_003504753.1 ACAAAAGCGAGCCCAAAGCGG 56
YKT6 Rev XM_003504753.1 GGCTCTGCTGCCTTTTGCTGA 56
EDEM1 Fwd NM_001246715.1 CTGCAATGAAGGAGAAGGGG 54
EDEM1 Rev NM_001246715.1 ACCTGCAGTCCAGGGAAGAA 54
CHOP (GADD153) Fwd EGW02276 GAGTCCCTGCCTTTTGCCTT 54
CHOP (GADD153) Rev EGW02276 CCCCTCTTCATTTCCAAGGG 54
ATF4 Fwd NM_001246812.1 CCTCTCCAGTTGTTACCCGT 54
ATF4 Rev NM_001246812.1 GCTGCTGTCTTGTTTTGCTCC 54
CHO GAPDH Fwd derived from 
NM_001244854.2
GGTGGTGAAGCAGGCATCTG 56
CHO GAPDH Rev derived from 
NM_001244854.2
GTCATTGAGAGCAATGCCAGC 54
131bp
116bp
152bp
193bp
132bp
133bp
114bp
143bp
142bp
